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A B S T R A C T
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the degeneration of
dopaminergic neurons and/or loss od neuronal projections, in several dopaminergic networks. Current
treatments for idiopathic PD rely mainly on the use of pharmacologic agents to improve motor
symptomatology of PD patients. Nevertheless, so far PD remains an incurable disease. Therefore, it is of
utmost importance to establish new therapeutic strategies for PD treatment. Over the last 20 years,
several molecular, gene and cell/stem-cell therapeutic approaches have been developed with the aim of
counteracting or retarding PD progression. The scope of this review is to provide an overview of PD
related therapies and major breakthroughs achieved within this ﬁeld. In order to do so, this review will
start by focusing on PD characterization and current treatment options covering thereafter molecular,
gene and cell/stem cell-based therapies that are currently being studied in animal models of PD or have
recently been tested in clinical trials. Among stem cell-based therapies, those using MSCs as possible
disease modifying agents for PD therapy and, speciﬁcally, the MSCs secretome contribution to meet the
clinical challenge of counteracting or retarding PD progression, will be more deeply explored.
© 2017 Elsevier Ltd. All rights reserved.
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Parkinson's disease (PD) is the most common motor-related
disorder in middle or late life, affecting millions worldwide
(Pereira and Aziz, 2006). It was ﬁrst described in 1817 by James
Parkinson on his original “An essay on the shaking palsy” as
“paralysis agitans”, after observing signs of tremor, festinating gait
and ﬂexed posture in six patients (Parkinson, 1817; Pereira and
Aziz, 2006). “Paralysis agitans” was later named “maladie de
Parkinson” or Parkinson's disease in 1888 by Charcot (Charcot,
2002). The scope of this review is to provide an overview on PD and
related therapies, including the most recent trends within this
ﬁeld. For that, it will ﬁrst characterize PD and will focus thereafter
on clinical features and diagnosis, as well as on current clinical
approaches and emerging molecular and stem cell-based thera-
pies, particularly those using mesenchymal stem cells (MSCs). An
overview of new candidate drugs and the current status of geneFig. 1. Summary of PD therapeutic approaches currently used in clinics or untherapy for PD treatment will also be provided. All the therapeutic
approaches outlined in this review aiming at treating the motor
symptoms of PD are summarized in Fig. 1.
2. Parkinson's disease
Parkinson's disease is a slowly progressive neurodegenerative
disease, primarily characterized by the increasing loss of dopami-
nergic (DAergic) neurons. This happens in several dopaminergic
networks (mesocortical, mesolimbic and nigro-striatal pathways),
presenting a stronger impact in the ventral tier of the substantia
nigra pars compacta (SNpc) within the mesostriatal/nigrostriatal
pathway (Cummins and Barker, 2012; Koller, 2003; Pereira and
Aziz, 2006; Teixeira et al., 2013). Loss of substantia nigra (SN)
neurons leads to less DAergic innervations and consequently to
striatal dopamine (DA) deﬁciency, the main responsible for most of
the sensory-motor symptoms of PD (Dauer and Przedborski, 2003).der research (* indicates current therapeutic approaches used in clinics).
A.O. Pires et al. / Progress in Neurobiology 156 (2017) 69–89 71By the time PD motor symptoms appear, approximately 60% of
DAergic neurons in SN and 80% of striatal DA terminals have
already been lost (Beach et al., 2008; Cheng et al., 2010; Dauer and
Przedborski, 2003; Nandhagopal et al., 2008). Although the
etiology of SN degeneration is unknown, in addition to the motor
symptomatology, the presence of Lewy bodies (LBs) is another
hallmark feature of PD and is typically used as a post-mortem
conﬁrmation of the disease (Olanow and Brundin, 2013). LBs are
distinctive intracytoplasmatic inclusions, containing a variety of
cellular proteins, being a-synuclein the most abundant one
(Benskey et al., 2016). The precise reason why LBs form and its
role in pathogenesis of PD remains undetermined (Dickson et al.,
2009). However, in recent years, it has become clear that the initial
sites displaying LBs are the dorsal motor nucleus of the vagus in the
brainstem and the olfactory bulb, which is described as stage I of
the disease. This staging was ﬁrstly proposed by Braak and
colleagues (Braak et al., 2003a), demonstrating that the disease
most likely progresses in an upward direction via the pons (stage
II) to the midbrain (stage III), followed by the basal prosencephalon
and mesocortex (stage IV), and eventually reaching the temporal
cortex and neocortex (stages V and VI) (Braak et al., 2003b).
However, it is only at stage III, when DAergic neuronal death and
striatal nerve terminals exceed a critical threshold (as mentioned
above) that motor features of PD become evident. This means that
there is a substantial pre-symptomatic period when the disease is
hidden possibly due to the existence of compensatory mechanisms
(Navntoft and Dreyer, 2016).
There has been converging evidence suggesting that PD can
start in the gut, before spreading to the olfactory bulb and caudal
brainstem and then progressing through the brainstem and the
diencephalon until it eventually reaches the cortex (Jankovic,
2016). Based on this idea, Gjerløff and colleagues (Gjerloff et al.,
2015) proposed that in addition to the loss in dopaminergic
innervation, catecholaminergic and cholinergic neurons are also
vulnerable and affected on PD (Gjerloff et al., 2015). Through an
imaging acetylcholinesterase (AChE) density of the peripheral
organs using positron emission tomography (PET), these authors
found not only loss of cholinergic innervation in the gastro-
intestinal tract, but also that the pancreas seems to be affected,
since it receives innervation from the dorsal vagal motor nucleus
(DMV). However, no studies have yet analyzed histologically the
distribution of cholinergic markers in PD patient's pancreas,
thereby raising the question about which structures within it
exhibit the decreased AChE expression and if this could be used as a
biomarker or a diagnostic strategy for PD (Gjerloff et al., 2015).
Approximately 5–10% of patients present the classical Mende-
lian inheritance form of PD (“familial PD”), with patients
presenting mutations in the genes that have been related to
neurodegeneration (e.g., a-synuclein, parkin, tau and ubiquitin c-
terminal hydrolase) (Bras and Singleton, 2009; Dexter and Jenner,
2013; Simon-Sanchez et al., 2009). In spite of that, the most
common form of PD is sporadic. It is believed that the interaction of
multiple genetic susceptibilities and environmental factors under-
lie the cause for this idiopathic form of PD (Dawson and Dawson,
2003; Di Monte, 2003). In addition, biochemical abnormalities
such as mitochondrial dysfunction, free radical mediated damage,
excitotoxicity, inﬂammatory change and proteasomal dysfunction
have also been reported to mediate PD pathogenesis (Dauer and
Przedborski, 2003; Schapira, 2005). Although it is well known that
DAergic neuronal loss is severe in the SNpc at later stages of PD,
there is a lack of information regarding the rate and magnitude of
this degeneration in the different stages of the disease, particularly
in the early stages after diagnosis. Indeed, Kordower and
colleagues (Kordower et al., 2013) have recently supported this
idea, proposing that such information may be crucial for
understanding the natural evolution of PD. By performing acorrelation between disease duration and integrity of the
nigrostriatal system, these authors found that although PD
progresses beyond the ﬁrst decade, the phenotypic changes in
the nigrostriatal pathway are greater than the structural changes.
This suggests that the clinical dysfunction that is observed is likely
due to a severe loss of function of the nigrostriatal neurons
(Kordower et al., 2013), which may be due to a degeneration of the
DAergic terminals and not its loss, thereby indicating that possibly
DAergic neurons may be dysfunctional but still potentially viable
and recoverable. Nevertheless, answers to these observations
require additional studies and tools, particularly in early stages of
the disease where there is a greater chance that surviving/viable
DAergic neurons beneﬁt from therapy.
2.1. Parkinson's disease clinical features
PD clinical features include a variety of motor and non-motor
symptoms. Since there are no deﬁnitive diagnostic tests for this
disease and it may often be confused with other parkinsonian
disorders (e.g., essential tremor, multiple system atrophy and
progressive supranuclear palsy), clinicians require thorough
knowledge of PD clinical manifestations to differentiate it from
other conditions. The discovery of new biomarkers speciﬁc for PD
could obviate this problem in the future.
From the motor point of view, PD is characterized by the
appearance of motor cardinal features namely bradykinesia,
resting tremor, rigidity, and postural instability (Jankovic, 2008;
Koller, 2003; Massano and Bhatia, 2012). At the onset of the
disease, patients typically present asymmetrical tremors, more
prominent in the upper extremities (Koller, 2003). As the disease
progresses, patients are equally affected on both sides of the body,
with bilateral bradykinesia becoming evident (Koller, 2003). Later
on, patients reveal postural instability, gait dysfunctions (freezing
and festination) and severe balance impairments, that frequently
lead to falls (Koller, 2003). Bradykinesia or slowness of movement
is the most characteristic clinical feature of PD (Jankovic, 2008),
that manifests by difﬁculties in initiation, execution and arrest of
movement, or in any task requiring ﬁne motor control (Jankovic,
2008; Koller, 2003). Tremor at rest, particularly in distal part of the
extremities, is also one of the most recognizable symptoms of PD
(Jankovic, 2008). Additionally present postural tremor, may also
represent a manifestation of PD (Jankovic, 2008; Koller, 2003).
Rigidity is characterized by increased resistance to muscle stretch
and relaxation, due to tightness and stiffness of muscles and may
occur proximally (e.g., neck, shoulders, hips), distally (e.g., wrists,
ankles) or both. It is often associated with pain (e.g., painful
shoulder) and, later in the disease, with postural deformities, such
as ﬂexed neck and trunk posture, as well as ﬂexed elbows and
knees (Jankovic, 2008; Koller, 2003). In later stages of PD, postural
instability also becomes evident as a result of loss of postural
reﬂexes. The latter is usually followed by freezing, a form of
movement loss (akinesia) characterized by a sudden transient
inability to move, contributing to loss of balance (postural
instability) and subsequent falls (Giladi et al., 2001; Jankovic,
2008; Koller, 2003). Although freezing does not occur universally,
it is probably the most disabling of all PD symptoms in more
advanced stages. Finally, in certain circumstances, particularly in
patients with postural instability and ﬂexed truncal posture,
festination of gait (involuntary quickening of gait) may also occur
(Koller, 2003).
Although PD is generally considered a motor control disorder
and the cardinal signs of the disease rely on motor disabilities, a
variety of non-motor features also emerge due to the degeneration
of other neuronal pathways (Koller, 2003). These non-motor
features are commonly known as PD non-motor symptoms and are
very frequent, contributing signiﬁcantly for the morbidity and
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2005; Shulman et al., 2001). They are characterized by neuropsy-
chiatric, autonomic, sensory and sleep abnormalities (Jankovic,
2008; Koller, 2003; Schapira, 2005). The most frequent neuropsy-
chiatric comorbidities include apathy (anhedonia), dementia,
anxiety disorders (e.g., panic attacks), depression, hallucinations,
psychosis and impulse control disorders (e.g., obsessive-compul-
sive and impulse behaviors) (Jankovic, 2008; Koller, 2003;
Schapira, 2005). Autonomic/involuntary nervous system control
dysfunctions affect about one third of PD patients (Koller, 2003).
The most common autonomic abnormalities are orthostatic
hypotension, sweating dysfunction, bowel problems, constipation,
dysphagia (swallowing difﬁculties), sialorrhoea (excessive pro-
duction of saliva), sphincter and erectile dysfunction (Jankovic,
2008; Koller, 2003; Schapira, 2005). Sensory disturbances also
affect PD patients, but often pass unrecognized as parkinsonian
disturbances (Koller, 2003; Shulman et al., 2002). These include
anosmia (lack of olfaction), akathisia (physical restlessness and
subjective urge to move), paresthesias (abnormal sensation of the
skin like burning, prickling and formication) and pain (Jankovic,
2008; Koller, 2003). Finally, sleep disturbances such as excessive
sleepiness, sleep attacks, insomnia as well as rapid-eye movement
sleep behavior, are also common in PD (Gjerstad et al., 2006, 2007;
Jankovic, 2008).
3. Current clinical therapies in Parkinson's disease
3.1. PD pharmacotherapies
The pioneer work of Carlsson and colleagues (1957) on the
discovery of DA as a putative neurotransmitter (Björklund et al.,
2010), together with the ﬁndings from Ehringer and Hornykiewicz
(1960) which revealed that dopamine concentrations were
markedly decreased in the striatum of PD patients (Ehringer and
Hornykiewicz, 1998), paved the way for the use of L-DOPA in the
clinical setting (Pandey, 2012; Smith et al., 2012). Indeed L-DOPAFig. 2. Wearing-off typical pattern revolutionized the treatment of cardinal motor symptoms of PD
(rest tremor, rigidity, bradykinesia and postural instability) leading
to improved daily function, quality of life and survival of PD
patients (Smith et al., 2012). Over the last decades, L-DOPA has
become known as the “gold standard” therapy for PD motor
symptoms. However, chronic use of L-DOPA often leads to motor
ﬂuctuations and drug-induced dyskinesias (Factor and Weiner,
2008; Schapira, 2005; Smith et al., 2012). The mechanisms
underlying these effects are not completely understood, but are
most likely related with the pulsatile stimulation of DA receptors
and the degree of striatal denervation (Obeso et al., 2000; Schapira,
2005). In an attempt to solve these motor complications, dopamine
receptor agonists started to be administrated, either alone or as
combinatorial therapy with L-DOPA (Lang and Lees, 2002;
Schapira, 2005; Smith et al., 2012). Nevertheless, the use of DA
receptor agonists is not free from motor disturbances, often
leading to major autonomic and psychiatric side effects that
outweigh their beneﬁcial effects in PD patients (Smith et al., 2012).
Currently, two oral (pramipexole, ropinirole), and one injectable
(apomorphine), DA receptor agonists are available for administra-
tion to these patients (Smith et al., 2012). They were developed to
reduce prevalence of drug-induced dyskinesias in PD patients and
their efﬁcacy was later conﬁrmed in large-scale randomized
controlled trials (Dewey et al., 2001; Parkinson Study Group, 2000;
Rascol et al., 2000). Besides having speciﬁc action in certain DA
receptors subtypes, pramipexole and ropinirole have longer half-
lives, which presumably avoids rapid ﬂuctuations in DA receptors
stimulation, thereby managing dyskinesias in such patients
(Schapira, 2005; Smith et al., 2012). However, although pramipex-
ole and ropinirole DA receptor agonists diminish the risk of
dyskinesias in PD patients, they often generate major non-motor
side effects like psychiatric symptoms (e.g., hypomania, euphoria,
paranoia, confusion, delusions, hallucinations), psychiatric disor-
ders (e.g., psychosis, depression, impulse control disorders),
autonomic side effects (e.g., orthostatic hypotension) and sleep
disorders (Factor, 2008; Kalinderi et al., 2011; Olanow et al., 2009b;during the day in PD patients.
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tion with L-DOPA will be required (Rascol et al., 2000; Schapira,
2005). Therefore, pramipexole and ropinirole are currently being
administrated as monotherapy early in the course of PD, or in
combination with L-DOPA in mid- to late-stages of the disease. On
the other hand, apomorphine is one of the oldest non-ergot short-
acting DA receptor agonists, with receptor afﬁnity (D1, D2, D3)
similar to the referred neurotransmitter (Factor, 2008; Smith et al.,
2012). Apomorphine is also the only DA receptor agonist that has
been shown to possess an anti-parkinsonian efﬁcacy similar to L-
DOPA in double-blinded clinical trials (Dewey et al., 2001; Koller,
2003; Smith et al., 2012). This similarity, together with the short-
acting activity of apomorphine, may explain the appearance of
autonomic side effects resembling those described for pramipex-
ole and ropinirole, although with a lower prevalence of psychiatric
problems (Dewey et al., 2001; Pfeiffer et al., 2007; Smith et al.,
2012). The use of apomorphine for treating PD has been avoided for
several years due to its emetic (vomit-inducing) action (Dewey
et al., 2001; Koller, 2003). But the development of an injectable
form (apomorphine hydrochloride) allowed to surpass these
limitations and nowadays apomorphine is used as an adjuvant
to other anti-parkinsonian medications (Dewey et al., 2001;
Pfeiffer et al., 2007; Smith et al., 2012). In spite of its beneﬁts,
reported technical difﬁculties and cutaneous adverse effects, after
long-term subcutaneous infusions, made this drug an unattractive
choice for PD treatment (Smith et al., 2012). As consequence,
injectable apomorphine is only used in unpredictable motor
ﬂuctuations (end-of-dose “wearing off”) and “off” episodes in later
stage PD patients (Koller, 2003) (Fig. 2).
Inhibitors of dopamine metabolizing enzymes like monoamine
oxidase B (MAO-B), (peripheral) cathecol-O-methyltransferase
(COMT) and aromatic L-aminoacid decarboxylase, are other agents
presently used for normalizing DAergic transmission. In 1962,
monoamine oxidase inhibitors were found to potentiate the anti-
parkinsonian effect of L-DOPA (Bernheimer et al., 1962; Koller,
2003).
Currently, selegiline and rasagiline are the most common MAO-
B inhibitors used in the treatment of PD (Peretz et al., 2016). Several
clinical guidelines have been established, proposing the initiation
of PD treatment with these drugs, in order to delay the
introduction of L-DOPA (Connolly and Lang, 2014; Olanow et al.,
2001). Indeed, the efﬁcacy of both drugs has been widely
supported (Jost et al., 2014). Stowe and colleagues (Stowe et al.,
2011) suggested in their meta-analysis that selegiline and rasagi-
line have comparable effects in the treatment of PD. However, this
assumption still remains under some controversy. Results from
ﬁve studies with selegiline and four with rasagiline revealed
similar effects in their treatment efﬁcacy (Marconi and Zwingers,
2014). Nevertheless, in an indirect meta-analysis performed by Jost
and colleagues (Jost et al., 2012), it was reported that rasagiline
takes advantage over selegiline, when the UPDRS total score is
used. Recently, Peretz and colleagues (Peretz et al., 2016) suggested
some possible advantage for selegiline, either because of better
symptomatic effects or superiority in its disease-modifying effects,
when compared to rasagiline.
Altogether, results revealed that selegiline and rasagiline were
effective in early stages of PD, leading to their current adoption as
monotherapy in early stages of PD. On the other hand, they can also
be used in combination with L-DOPA to reduce motor ﬂuctuations
and “off” episodes in advanced PD patients (Factor, 2008; Group,
2005a; Kalinderi et al., 2011; Olanow et al., 2008a, 2009a,b;
Parkinson Study Group, 1989, 2002; Rascol et al., 2011). It is also
worth mentioning that MAO-B inhibitors were suggested to act as
neuroprotective agents (Akao et al., 2002; Bar Am et al., 2004;
Jenner, 2004; Maruyama et al., 2002). However, their potential for
displaying neuroprotective properties has been surrounded bycontroversy (Hart et al., 2009; Olanow et al., 2008a,b; Rascol,
2009). As reviewed by Knudsen Gerber (2011) both selegiline and
rasagiline have been suggested to withhold neuroprotective
properties. Still, for selegiline studies have yet to show a deﬁnitive
conclusion (Fernandez and Chen, 2007). Meanwhile, the use of
rasagiline in clinical studies also demonstrated a delayed and
reduced need for future use of L-DOPA (Group, 2005a).
Inhibitors for COMT (e.g., tolcapone, entacapone) and aromatic
L-aminoacid decarboxylase (e.g., carbidopa), have been developed
to improve the L-DOPA therapeutic effect (Koller, 2003). Demon-
stration of COMT inhibitors (e.g., antacapone, tolcapone) effective-
ness in decreasing motor ﬂuctuations in advanced PD patients,
when combined with L-DOPA or with L-DOPA-carbidopa (Heikki-
nen et al., 2002; Larsen et al., 2003; Nutt et al., 1994; Parkinson
Study Group, 1997; Poewe et al., 2002; Rinne et al., 1998; Schapira,
2005; Smith et al., 2012), led to FDA approval for their clinical use.
Anticholinergics are amongst the oldest class of pharmaceut-
icals used as therapeutic agents for the management of PD (Factor
and Weiner, 2008; Koller, 2003; Smith et al., 2012). Considered the
ﬁrst treatment for PD, the effectiveness of anticholinergic treat-
ments was postulated in the theory stating that the origin of PD
motor symptoms was the result of an imbalance between
acetylcholine and dopamine in the striatum (Aosaki et al., 2010;
Kalinderi et al., 2011). However, over the years their use has
declined, due to the introduction of L-DOPA and dopamine agonists
(Aosaki et al., 2010). Nowadays, it is mainly clinically adopted for
the treatment of young patients with PD-associated tremor or
dystonia (Koller, 2003; Smith et al., 2012).
Amantadine is another FDA approved anti-parkinsonian agent.
It acts by blocking glutamatergic hyperactivity, which has been
associated with PD pathology (Rascol et al., 2011; Smith et al.,
2012). It is the only ionotropic glutamate receptor antagonist that
has been shown to have robust antidyskinetic properties in the
reduction of L-DOPA-induced dyskinesias (Factor, 2008; Kalinderi
et al., 2011; Olanow et al., 2009b; Smith et al., 2012). Therefore, it is
the only drug currently used capable of concomitantly reduce
dyskinesia and improve PD symptoms (Ferreira and Rascol, 2000;
Koller, 2003).
A summary of study design and number of patients as well as
primary outcome measure, main results and conclusions from trial
studies above referenced is provided in Table 1.
3.2. PD surgical interventions
The ﬁrst reports showing that surgery interventions within the
basal ganglia could resolve tremor and rigidity came from the work
published by Russel Meyers in 1942 and 1951 (Meyers, 1942, 1951).
Following this, several groups conducted surgeries based in
ablative techniques. At the time, surgical ablation was performed
in different basal ganglia locations, such as the anterodorsal and
posteriomedial segments of the pallidum (pallidotomy), as well as
the ventrolateral and the ventral intermediate segments of the
thalamus (thalamotomy) (Alexander et al., 1990; Jankovic et al.,
1995; Koller, 2003). As a consequence of the reported beneﬁts of
this type of surgery in improving tremor and rigidity, ablative
surgeries (pallidotomy, thalamotomy) became the standard
procedure for treatment of PD motor symptoms between the
1950s and the 1960s (Pandey, 2012). In the 1960s, with the advent
of L-DOPA as an effective drug for PD motor symptoms, surgery for
PD gradually declined. However, several other events in the past
twenty-ﬁve years contributed for the reemergence of neurosurgi-
cal interventions for PD management. For instance, reversible
lesioning by deep brain stimulation (DBS), pioneered by Cooper in
the early 1970s (Cooper, 1973; Pereira and Aziz, 2006), as well as
the outcomes provided by non-human primate models of PD in
understanding basal ganglia pathophysiology (Aziz et al., 1991;
Table 1
Summary of key clinical trials conducted using current drug options for treatment of PD patients’ motor symptomatology.
References Drug(s) Study design Patients Nr. of
subjects
Primary outcome measure Results
Parkinson
Study Group
(1989)
DATATOP
study
Selegiline vs.
Tocopherol
RD, DB, PC;
25 months
Early
untreated
800 Extends the time until
disability requires therapy
with L-DOPA
Selegiline delayed the onset of L-DOPA therapy and slowed
parkinsonism disability. Disease-modifying effects of selegiline
were not found.
Nutt et al.
(1994)
Entacapone + L-
DOPA
Unblinded; 8
weeks
Advanced
ﬂuctuations
15 Effect of entacapone in L-
DOPA pharmacokinetics
and pharmacodynamics
The inhibition of COMT by entacapone decreases the plasma
elimination of L-DOPA and enhances the antiparkinsonian
effects of single and repeated doses of L-DOPA.
Parkinson
Study Group
(1997)
SEESAW
study
Entacapone + L-
DOPA
MC, DB, PC,
PG, MD; 24
weeks
Advanced
ﬂuctuations
205 Changes in “on” time Entacapone is generally effective in subjects with motor
ﬂuctuations, extending the beneﬁts of L-DOPA and ameliorating
the symptoms of PD. Patients with the greatest amount of off-
time periods are those who are most likely to beneﬁt from this
drug.
Rinne et al.
(1998)
Nordic
NOMECOMT
study
Entacapone + L-
DOPA
RD, PC, DB,
PG; 6
months
Advanced
ﬂuctuations
171 Changes in on-time and off-
time periods
Long-term entacapone treatment effectively prolonged the
effect of L-DOPA, increasing the on-time, and reducing the off-
time and L-DOPA daily dosage; Increase in UPDRS scores.
Rascol et al.
(2000)
Part of 056
study
Ropinerole vs.
L-DOPA
RD, DB, PG; 5
years
Early
untreated
268 Occurrence of dyskinesias The cumulative incidence in dyskinesias after 5 years follow-up
was lower in ropinerole group when compared with L-DOPA
alone. Adverse effects: higher incidence of hallucinations in
ropinerole group and similar incidence of nausea among groups.
Parkinson
Study Group
(2000)
CALM-PD
study
Pramipexole
vs. L-DOPA
MC, RD, DB,
PG; 4 years
Early
untreated
301 Time to occurrence of motor
complications
Initial pramipexole treatment reduced the risk of developing
motor complications, but was not as potent as L-DOPA in
improving the parkinsonian features (measured by UPPERS).
Adverse effects: somnolence, hallucinations, generalized and
peripheral edema in patients treated with pramipexole.
Parkinson
Study Group
(2002)
TEMPO study
Rasagiline MC, RD, DB,
PC, PG, MD;
26 weeks
Early
untreated
404 Change in UPPERS (I, II, III,
IV)
Rasagiline induced an increase in UPPERS III when compared to
placebo treatment. Further studies are needed to evaluate
rasagiline long-term effect.
Larsen et al.
(2003)
(extension of
NOMECOMT
study)
Entacapone + L-
DOPA
RD, DB, PC,
PG; 3 years
Advanced
ﬂuctuations
132 Change in off-time period Entacapone increased the beneﬁt of L-DOPA single dose and
decreased the off-time period. Adverse effects: diarrhea,
insomnia, dizziness, nausea, and hallucinations.
Group (2005a)
PRESTO
study
Rasagiline MC, RD, DB,
PC, PG, MD;
26 weeks
Advanced
ﬂuctuations
472 Change from baseline in
total daily off-time and
adverse event frequency
Rasageline decreased daily off-time and improved the motor
ﬂuctuations and PD symptoms in L-DOPA treated patients.
Pfeiffer et al.
(2007)
Apomorphine RD, DB, PC; 3
months
Advanced
ﬂuctuations
62 Change in UPPERS motor
score
Apomorphine increased UPPERS vs. placebo. No signiﬁcant
differences in adverse side effects. Decrease in daily off episodes.
Olanow et al.
(2008a,
2009a)
ADAGIO
study
Rasagiline DB, DS, MD;
72 weeks
Early
untreated
1176 Change in UPPERS (I, II, III,
IV)
Early treatment with rasagiline at a dose of 1 mg/day provided
beneﬁts (e.g.: increase in UPPERS scores), consistent with a
possible disease-modifying effect. However, early treatment of
rasagiline with 2 mg/day did not. Therefore, rasagiline disease
modifying effects must be interpreted with caution.
Key: CO (cross-over); DB (double-blind); DS (delayed start); MC (multicenter); MD (multi-dosage); PC (placebo controlled); PG (Parallel group); RD (randomized); UPPERS
(Uniﬁed PD rating scale); UPPERS I: evaluates mental cognition, behavior and mood disabilities; UPPERS II: evaluates quality of life/activities of daily life disabilities; UPPERS
III: evaluates motor impairment; UPPERS VI: evaluates complications of therapy.
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the “renaissance” of neurosurgical therapies for PD.
Approved by FDA in 2002, DBS consists in the implantation of
internal and external electric stimulators (like a pacemaker device)
with the aim of delivering continuous high frequency electric
stimulation to areas within the brain (Faggiani and Benazzouz,
2016; Schwalb and Hamani, 2008; Smith et al., 2012). In fact, when
compared to the ﬁrst surgical procedures in this area, DBS has
overtaken pallidotomy in developed countries, since it presents
less signiﬁcant risks (e.g., hemorrhage, infarction, facial palsy,
dysphagia, mortality) and adverse effects (e.g., affective disorders;
visual ﬁelds, speech and cognitive deﬁcits) than the latter (Pereira
and Aziz, 2006; Rascol et al., 2011). DBS of the subthalamic nucleus
(STN) and the internal pallidal segment (internal globus pallidus/
GPi) is currently the most commonly applied surgical treatment in
patients with tremor, dyskinesias, rigidity and motor ﬂuctuations
refractory to the presently available medication (Benabid et al.,
2009a,b; Pereira and Aziz, 2006; Rascol et al., 2011; Smith et al.,
2012). Nevertheless, the ideal target for DBS is still a matter ofdebate. In fact, clinical trials have related STN DBS to signiﬁcant
cognitive and psychiatric side effects, such as depression, apathy,
impulsivity, emotional instability and increased risk of suicide
(Anderson et al., 2005; Follett et al., 2010; Moro et al., 2010; Okun,
2013; Schupbach et al., 2005; Soulas et al., 2008; Strutt et al., 2012;
Taba et al., 2010). The underlying cause for these events, when
reported following DBS surgery either in STN or in the GPi, has not
yet been established, but it is thought to involve stimulation of
non-motor areas of these targets, along with the limbic structures,
as well as pre-surgical psychiatric conditions (Follett et al., 2010;
Okun et al., 2009). A summary of the type of surgery, study design,
duration and number of patients as well as the primary outcome
measure, main results and conclusions from trial studies
referenced in this section is provided in Table 2.
3.3. New drugs and surgical targets for PD
Motor complications associated with long-term L-DOPA treat-
ment, as well as the suggestion that some drugs (e.g., selegiline,
Table 2
Summary of key clinical trials conducted using functional neurosurgery for treatment of PD patients’ motor symptomatology.
References Drug(s) Study design Patients Nr. of
subjects
Primary
outcome
measure
Results
Anderson et al.
(2005)
Bilateral
STN vs.
GPi DBS
Blinded, RD,
PG; 12
months
Prominent
bradykinesia
and rigidity
25 UPPERS III in
off-
medication
Stimulation in STN or GPi improves off-medication motor scores and L-DOPA-
induced dyskinesia for at least 1 year. There is no clear superiority of STN over
GPi. Selection of stimulation site should be inﬂuenced by symptom proﬁle.
Schupbach et al.
(2005)
Bilateral
STN DBS
Unblinded;
5 years
Severe
L-DOPA
responsive PD
37 UPPERS III,
UPPERS II
Improvement in UPPERS III and UPPERS II scores. The signiﬁcant improvement
of motor function was sustained 5 years after neurosurgery.
Soulas et al.
(2008)
Bilateral
STN DBS
Unblinded;
6 months
Advanced PD 200 Suicidal
behavior
Two patients (1%) committed suicide and four patients (2%) attempted suicide
after surgery, despite fair to excellent motor improvement. Suicidal behavior is
a serious potential hazard of STN DBS, and is commonly associated with
depression. Other risk factors like increased impulsiveness may also play a
part.
Moro et al.
(2010)
Bilateral
STN and
GPi DBS
DB, CO; 5–6
years
Advanced PD 51 UPPERS III Effectiveness of both STN and GPi DBS in improving L-DOPA-responsive PD
signs, L-DOPA-induced dyskinesias, and ADEL. Adverse effects more frequent in
STN DBS group.
Follett et al.
(2010)
Bilateral
STN vs.
GPi DBS
Blinded, RD;
24 months
Advanced PD 299 UPPERS III Similar improvement in motor function after either GPi or STN DBS. Use of
DAergic medications decreased more in patients undergoing STN stimulation.
Okun (2013)
and Taba et al.
(2010)
Unilateral
vs.
Bilateral
DBS
GPi vs.
STN
Unblinded,
RD; 6
months
Advanced PD 44 UPPERS III,
UPPERS IV
Bilateral implantation more suitable for patients with high III-III scores, more
symmetric PD, severe gait dysfunction, or dyskinesias. Unilateral DBS suitable
for patients with asymmetric UPPERS III scores and moderate gait
disturbances.
Key: DBS (Deep brain stimulation); GPi (internal globus pallidus), subthalamic nucleus (STN); CO (cross-over); DB (double-blind); PG (Parallel group); RD (randomized);
UPPERS (Uniﬁed PD rating scale); UPPERS III: evaluates complications of therapy; UPPERS VI: evaluates complications of therapy; ADEL: activities of daily living;.
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development of new drugs for symptomatic or neuroprotective
therapies. Symptomatic drug therapies for motor features of PD,
already being tested in clinical trials, involve for instance the use of
DAergic drugs such as controlled-release formulations (IPX 066),
continuous duodenal infusions of carbidopa-levodopa (LCIG/
Duodopa) and sustained release formulations of L-DOPA (XP
21279). Other strategies have been followed, namely by using
drugs targeting non-DAergic neurotransmitter systems, such as
adenosine receptor antagonists (e.g., preladenant; tozadenant;
caffeine), alpha-2-adrenergic antagonists (e.g., ﬁpamezole), nor-
adrenergic reuptake inhibitors (e.g., methylphenidate), ionotropic
(e.g., talampanel) or metabotropic glutamate receptor antagonists
(e.g., mavoglurant, dipraglurant), serotonin receptor agonists (e.g.,
sarizotan, pardoprunox), nicotinic receptor agonists (e.g., nicotine),
histamine receptor antagonists (e.g., famotidine), cholinesterase
inhibitors (e.g., donepezil, rivastigmine), calcium channel blockers
(e.g., isradipine) and endogenous neurotrophic factor inducers (e.g.,
cogane) [more information on this topic can be found in Hauser
(2011), Kalia et al. (2013) and Rodnitzky (2012)]. Some of the above
referred drugs (e.g., nicotine, preladenant) are also being studied in
clinical trials for the potential neuroprotective part they can play in
the scope of PD (source: clinicaltrials.gov; clinical trial identiﬁers:
NCT01560754, NCT01155479) [more information on this topics in
Dunkel et al. (2012) and Kalia et al. (2013)]. On the other hand, new
drugs targeting oxidative-stress (e.g., deferiprone), mitochondrial
dysfunction and excitotoxicity (e.g., creatine) (Rascol et al., 2011;
Schapira, 2005) are also currently being tested in clinical trials
(NCT01539837, NCT00449865) to determine their possible neuro-
protective role in PD [reviewed by Dunkel et al. (2012), Kalia et al.
(2013) and Rodnitzky (2012)].
Electrode implantation in patients has also provided insight
into the patho-anatomy and pathophysiology of PD. These
progresses led to the establishment of possible new targets for
DBS such as pedunculo pontine nucleus and caudal zona incerta
[reviewed by Sackeim and George (2008)]. These targets generated
interest for DBS in PD patients since some small clinical trials
reported anti-parkinsonian effects following the stimulation ofeither pedunculo pontine nucleus (Ferraye et al., 2010; Plaha and
Gill, 2005) or zona incerta (Kitagawa et al., 2005; Plaha et al., 2006).
Therefore, new clinical trials are planned to study pedunculo
pontine nucleus (NCT01485276, NCT02318927) and zona incerta
(NCT01945567) as potential DBS targets for PD therapy.
4. Molecular therapies
As discussed before, the long-term use of L-DOPA has been
associated with undesirable side effects, such as motor ﬂuctuations
and dyskinesias (Schapira, 2005; Smith et al., 2012; Teixeira et al.,
2013). These limitations, together with signiﬁcant advances made
in the study of the pathobiology and patho-anatomy of PD, led to
the emergence of new pharmacologic agents and gene engineering
approaches for the long-term outcome of PD patients.
4.1. Drug therapy
Nowadays, new candidate drugs, still in preclinical studies,
focus mainly on neuroprotective agents, as well as on alternative
non-DAergic therapies, for PD treatment. Based on recent animal
model studies, metabotropic glutamate receptor agonists have
raised special attention as potential neuroprotective targets in PD
(Marino and Conn, 2006). Among the type of agonists mentioned,
subtype 4 of group III (mGluR4) is mainly localized in presynaptic
terminals and mediates inhibitory effects on basal ganglia
circuitry, namely on glutamatergic synapses in the striatum and
GABAergic synapses in the globus pallidus (Nicoletti et al., 2011;
Smith et al., 2012). DA depletion in PD has been associated with
basal ganglia circuitry hyperactivation. Electrophysiological stud-
ies have demonstrated that activation of mGluR4 signiﬁcantly
reduces excitatory synaptic transmission within the basal ganglia
(Bennouar et al., 2013; Cartmell and Schoepp, 2000). For these
reasons, interest has been raised about the use of mGluR4 agonists,
and more recently about enhancers of the mGluR4 agonist effect
(positive allosteric modulators), as potential anti-parkinsonian
therapies. Indeed, several studies have shown that drugs which
activate mGluR4, such as orthosteric agonists (e.g., (2S)-2-amino-
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yl]phosphoryl]butanoic acid/LSP1-2111) and positive allosteric
modulators [(e.g., N-phenyl-7-(hydroxylimino)cyclopropa[b]chro-
men-1a-carboxamide (PHCCC); (+/)-cis-2-(3,5-dichlorphenylcar-
bamoyl)cyclohexanecarboxylic acid/VU0155041, and 5-Methyl-N-
(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2amine/
ADX88178)], crossed the brain–blood-barrier and alleviated PD
motor symptoms (e.g., akinesia and drug-induced dyskinesias) in
animal models (Betts et al., 2012; Beurrier et al., 2009; Niswender
et al., 2008). For instance, allosteric modulators like PHCCC have
shown to reduce loss of nigrostriatal dopaminergic neurons in a
mice model of PD, following its injection in the external globus
pallidus (Battaglia et al., 2006). Similar results regarding neuro-
protection of DAergic neurons and motor beneﬁts were reported by
Betts et al. after injection of VU0155041 in the SNpc of a rat model
of PD (Betts et al., 2012). These results suggest that mGluR4
allosteric modulators may play a dual role, by relieving PD motor
symptoms and providing neuroprotection of the nigrostriatal
pathway. Indeed, recently developed positive allosteric modula-
tors, like ADX88178, demonstrated to improve efﬁcacy in a rodent
PD model when combined with L-DOPA and adenosine receptor
antagonists (Amalric et al., 2013; Celanire and Campo, 2012). Taken
together, current experimental data on mGluR4 agonist effects on
general PD motor symptoms and neuroprotection of the nigros-
triatal pathway are promising. Importantly, non-motor side effects
should also be assessed in future animal studies. This is a matter to
be taken in account, since it was reported in human studies
following administration of several ionotropic glutamate receptor
antagonists, aimed at blocking increased glutamatergic transmis-
sion in the basal ganglia circuitry (Maranis et al., 2012).
In addition to mGluR4 agonists, CEP-1347 has also been
proposed as a possible disease modifying agent for the treatment
of PD (Parkinson Study, 2004). CEP-1347 has been described as an
anti-apoptotic drug able to inhibit the mixed lineage kinases,
which are activators of apoptotic pathways implicated in the
pathogenesis of PD (Eggert et al., 2010). From the application point
of view, this drug was found to enhance neuronal survival in a
variety of pre-clinical models and also to be safe and well tolerated
in PD (Harikrishna Reddy et al., 2014). Indeed, CEP-1347 did not
alter the pharmacokinetics of L-DOPA in PD patients, when both
you administered in combination (Parkinson Study, 2004). Despite
these promising observations, application of CEP-1347 remains
controversial. In 2007, The Parkinson Study Group PRECEPT
Investigators (Parkinson Study Group, 2007) reported that,
contrarily to the effects showed in animal models (CEP-1347
acting as a favorable disease-modifying agent), in humans CEP-
1347 demonstrated to be an ineffective treatment in early PD.
Similar results were also found in a phase II clinical trial conducted
with approximately 800 participants, which was terminated
because CEP-1347 did not cause any signiﬁcant decline in PD
progression (Group, 2005b).
GM1 ganglioside has also been described, like CEP-1347, as a
potential disease modifying therapy for PD (Pope-Coleman et al.,
2000; Schneider et al., 1998). Being a normal constituent of nerve
cell membranes, it is described as a modulator of several cell
surface and receptor activities. It also plays a role in neuronal
differentiation, protein phosphorylation and synaptic function
(Pope-Coleman et al., 2000; Schneider et al., 1995). GM1 has
demonstrated to be effective in ameliorating neurochemical and
behavioral alterations both in murine and non-human primate PD
models (Herrero et al., 1993; Schneider et al., 1995). In 1998,
Schneider and colleagues (Schneider et al., 1998), in a randomized
double blind placebo trial, showed that the administration of GM1
led to the improvement of UPDRS motor scores and performance in
motor tasks from PD patients, when compared to the baseline
performance. More recently, in a ﬁve-year open study, Schneiderand colleagues (Schneider et al., 2010) demonstrated that the long-
term application of GM1 in PD patients is safe and may provide
some clinical beneﬁts. Nonetheless, these authors also claim the
need for future studies to completely address if GM1 may be a
symptomatic or disease modifying compound for the treatment of
PD (Schneider et al., 2013, 2010). Following this, in a recent pilot
imaging study Schneider and colleagues (Schneider et al., 2015)
provided insights about the application of GM1 improving
dopamine neurotransmission in patients, which might indicate
GM1 as potential disease modifying agent for PD. Although the
precise mechanism for this has not been described, studies have
claimed that GM1 action in PD patients is multi-factorial
(Schneider et al., 2013). Indeed, in a recent work performed by
Hadaczek and colleagues (Hadaczek et al., 2015) it was suggested a
potential neuroprotective role of GM1, through GDNF signaling, an
important growth factor for the maintenance of DAergic viability.
Coenzyme Q10 (CoQ10), a pivotal enzyme in the oxidative
phosphorylation process in mitochondria, has also been presented
as a potential disease modifying agent for the treatment of PD (Seet
et al., 2014). However, the clinical evidence for CoQ10 in PD is still
conﬂicting. For instance, Muller and colleagues (Muller et al., 2003)
showed signiﬁcant symptomatic improvements following CoQ10
administration during four weeks, while similarly, Shults and
colleagues (Shults et al., 2002) observed long-term beneﬁts of
CoQ10 up to 16 months. On the other hand, Storch and colleagues
(Storch et al., 2007), using the same dose that the previous study
reported (1200 mg/day), did not observe beneﬁts in mid-stage PD
after 3 months of treatment. More recently, in a phase III
randomized clinical trial (Parkinson Study Group et al., 2014), it
was demonstrated that CoQ10 was safe and well tolerated in PD
patients, but did not present evidence of clinical beneﬁts. Thus,
additional trials are still needed to really conﬁrm the potential role
of CoQ10 in slowing or modifying the progressive deterioration
function in PD.
Finally, N-acetyl-cysteine (NAC) has been described as a thiol
antioxidant and a prodrug which can systematically deliver
cysteine to the brain (Martinez Banaclocha, 2000; Tarazi et al.,
2014). Studies in animal models have reported that NAC
administration leads to the reduction of oxidative damage, by
increasing mitochondrial complex I activities and preventing ROS
accumulation, leading this way to the protection of dopamine-
induced cell death (Clark et al., 2010; Martinez-Banaclocha, 2012).
In a recent clinical trial, Holmay and colleagues (Holmay et al.,
2013) demonstrated that, after intravenous injection of NAC, there
was a boost in antioxidant glutathione levels on the brain and
blood of PD patients. Such increases may compensate the
hypothesized deﬁciency and lower glutathione activity in PD
(Jenner, 2003, 2007). More recently, Monti and colleagues (Monti
et al., 2016) revealed that NAC may support DAergic viability and
functionality through dopamine modulation. Nevertheless, more
studies are still needed to investigate the potential beneﬁts of NAC
in improving PD symptomatology or slowing its progression,
whether as a monotherapy, whether or in combination with L-
DOPA.
4.2. Gene therapy
Gene therapy in PD makes use of viral vectors to carry out gene
transfer for targeted protein expression in speciﬁc brain areas. In
the last decade, the use of gene therapy to relieve PD motor
symptoms has reached clinical trials essentially through three
approaches: (1) delivery of glutamic acid decarboxylase (GAD)
enzyme in the STN; (2) delivery of synthetic enzymes to increase
striatal DA levels, and (3) local infusion of neurotrophic factors to
protect and restore nigral DAergic neurons (Cummins and Barker,
2012; Rodnitzky, 2012; Smith et al., 2012).
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rate-limiting enzyme for GABA synthesis, into the glutamatergic
neurons of the STN, using an adeno-associated virus (AAV) vector.
This gene therapy approach aims at modulating STN activity, by
modifying the phenotype of the STN neurons from predominantly
excitatory (glutamatergic) to predominantly inhibitory (GABAer-
gic). With this it is expected that the normal function in striato-
pallidal circuitry can be restored (Coune et al., 2012; Smith et al.,
2012). Based on preclinical data provided by animal models of PD
(Emborg et al., 2007; Lee et al., 2005; Luo et al., 2002), as well as the
reported improvement of motor scores in a phase I open-label
study involving 12 moderately advanced PD patients (Kaplitt et al.,
2007), a phase II, double-blind, randomized, sham-controlled trial
enrolling 45 advanced PD patients, was conducted (LeWitt et al.,
2011). Results revealed a modest but signiﬁcant improvement in
UPDRS motor scores of patients bilaterally infused with STN AAV-
GAD. The most common adverse effects reported were nausea,
headache and depression. A ﬁve year follow up of adeno-
associated virus serotype 2 (AAV2) vector encoding glutamic acid
decarboxylase in the subthalamic nucleus (STN AAV2-GAD) is
currently on-going to evaluate long-term effects of AAV-GAD gene
transfer and its long-term safety (NCT01301573).
The second gene therapy approach consists of the transfection
of dopamine-synthesizing enzymes, to induce DA synthesis in the
striatum in order to alleviate PD motor symptoms. So far, two
different enzyme replacement therapies have been tested in
clinical trials. In the ﬁrst open label phase I/II trial conducted in
2007, a lentiviral vector containing the genes encoding for the
enzymes required for DA biosynthesis (tyrosine hydroxylase/TH,
guanosine 50-triphosphate/GTP cyclohydrolase 1 and aromatic
amino acid decarboxylase/AADC), under the name of ProSavin, was
injected into the striatum to evaluate the safety, efﬁcacy and
dosage in 15 mid-to-late stage PD patients, for a period of 6 months
(NCT00627588). The Oxford biomedical company recently
reported good tolerance of ProSavin. Moreover, motor improve-
ments were observed 6 months after the test had begun, as
assessed by UPDRS motor scores. A multicenter, open label study
for a ten-year follow-up of patients who were treated with
ProSavin to evaluate its long-term safety, tolerability and efﬁcacy
for PD treatment is currently ongoing (NCT01856439). The second
enzyme replacement therapy, tested in two phase I clinical trials,
consisted in bilateral intra-putaminal or intrastriatal delivery of an
AAV encoding human AADC gene to induce local conversion of
peripheral administered L-DOPA into DA (Christine et al., 2009).
Although preclinical studies in a non-primate model of PD had
previously showed that AAV-AADC could induce stable long-term
expression of the vector, restore L-DOPA levels, improve motor
deﬁcits and reduce L-DOPA side effects in subjects (Bankiewicz
et al., 2006, 2000), both phase I clinical trials reported only modest
improvements in UPDRS scores of advanced PD patients. Moreover,
in one of the clinical trials (Christine et al., 2009), some patients
suffered from aggravated dyskinesias, most likely due to non-
regulated striatal neurons release of DA. A non-randomized open
label trial to evaluate safety and efﬁcacy of AAV2-human AADC
injected through magnetic resonance imaging guidance is
currently being planned (NCT01973543). However, future trials
must be designed with caution to avoid excessive production of
dopamine in the striatum, since GABAergic striatal neurons do not
possess vesicular storage capability. This lack of vesicular
structures can result in accumulation of extracellular or cytosolic
DA, which in turn may lead to oxidative-stress (Chen et al., 2008),
dyskinesias (Bankiewicz et al., 2006, 2000) and even to degenera-
tion of striatal neurons (Chen et al., 2008; Cyr et al., 2003).
The third gene therapy approach relies on the use of growth
factors, such as GDNF, to mediate growth, survival and protection
of DAergic neurons within the midbrain (Sherer et al., 2006). Dueto its tropism for the nigral DAergic neurons, GDNF was amongst
the ﬁrst molecules to be studied (Ai et al., 2003; Grondin et al.,
2003, 2002). However, two double-blind trials reported no
improvement of Parkinson motor symptoms following infusion
of GDNF, either in the lateral ventricles or in the putamen, with
many patients suffering from diverse side effects (Lang et al., 2006;
Nutt et al., 2003). Based on these results, the attention has shifted
toward neurturin (NTN), a member of the GDNF ligands family
that, similarly to GDNF, has shown to promote survival and growth
of midbrain DAergic neurons (Kotzbauer et al., 1996). Recently, the
efﬁcacy and safety of an adenovirus vector encoding for human
NTN (AAV2-NTN), under the name CERE-120, has been evaluated in
two clinical trials. A phase I clinical trial enrolling 12 PD patients
demonstrated good tolerance to AAV2-NTN and an improvement
in “off” medication symptoms (Marks et al., 2008). This led to a
phase II multicenter, randomized, double-blind, sham-controlled
trial involving intraputaminal injection of AAV2-NTN in 58 patients
with moderate to severe PD (Marks et al., 2010). However, in this
new study results revealed no improvements in UPDRS motor “off”
score. Also, contrarily to the results observed in pre-clinical non-
human primate studies (Herzog et al., 2008, 2007; Kordower et al.,
2006), post-mortem brain analysis of AAV2-NTN treated patients
revealed the expression of NTN mainly in the striatum with
minimal presence in the SNpc (Marks et al., 2010). This result has
been associated with the lack of retrograde transportation of NTN
to the SNpc and the extensive loss of DAergic neurons in advanced
PD patients (Bartus et al., 2011). Consequently, a new phase I/II
trial, in which AAV2-NTN is injected into the SN and the putamen,
is presently being conducted in earlier stage patients to evaluate
safety and potential beneﬁcial effects of AAV2-NTN over longer
periods of time (NCT00985517). So far, phase I has been completed
in 6 subjects with no reported complications.
In spite of the encouraging preclinical data, clinical trials based
on therapeutic transgenes delivery to basal ganglia neuronal
populations failed to conﬁrm the beneﬁcial motor effects observed
in animal studies (with the exception of the ﬁrst approach). This
way, genetic approaches still have to prove its long-term efﬁcacy
and long-term safety as an alternative therapy for the existing
symptomatic treatments. Nevertheless, recent insights on the
genetic causes of PD, as well as the development of innovative gene
delivery systems, may shed some light on this topic in the years to
come.
5. Cell-based therapies
The hypothesis that therapies using cells could be a good
strategy to replace DAergic neurons lost along the course of PD, led
to the emergence of cell-based approaches to meet the clinical
challenge of restoring degenerated DAergic neural circuitries and
provide long-lasting relief of patients symptoms. In this section,
the characterization, advantages and disadvantages of each of
these cell-based therapies will be further explored.
A summary of the advantages and disadvantages of different
stem cell types for application in PD is provided in Table 3.
5.1. Fetal ventral mesencephalic tissue
Fetal ventral mesencephalic (FVM) tissue is derived from the
fetuses’ midbrain (Shamekh et al., 2008). The rationale for its
transplantation relied on the hypothesis that healthy DAergic
neurons are able to reinnervate the striatum and restore
physiological DA transmission in the brain. In the late 1970s,
several grafting studies were conducted using FVM tissue trans-
planted either into the lateral ventricle adjacent to the caudate
(Perlow et al., 1979) or directly into the striatal parenchyma
(Björklund et al., 1980), on 6-hydroxydopamine (6-OHDA) models
Table 3
Advantages and disadvantages of different stem cell types for application in PD.
Cell
type
Advantages Disadvantages References
ES
cells
 High proliferative pluripotent cell source
 Retain pluripotency for long periods of in vitro
expansion
 Can be differentiated into DAergic neurons
 Derived DAergic neurons were shown to survive,
integrate and reinnervate the striatum of the host,
thus improving functional recovery of PD symptoms
 Risk of tumor formation related with
phenotypical instability of grafts
 Ethical concerns
 No data in non-human primate models of PD
Bj&rklund et al. (2002), Brederlau et al. (2006), Kim
et al. (2002), Politis and Lindvall (2012a,b), Roy et al.
(2006) and Salgado et al. (2006)
Fetal
NSCs
 Expandable multipotent cell source
 Can be differentiated into DAergic neurons
 Midbrain NSCs-derived DAergic neurons were
shown to survive, differentiate, migrate and induce
functional recovery in PD animals
 Limited differentiation in vivo
 Technical problems obtaining homogenous
populations of DAergic neurons
 Safety issues related with the use of retroviral
vectors for differentiating adult NSCs into
DAergic neurons
 Ethical concerns
Carvey et al. (2001), Parish et al. (2008), Politis and
Lindvall (2012b), Sanchez-Pernaute et al. (2001),
Sawamoto et al. (2001) and Schwarz et al. (2006)
iPS
cells
 Expandable cell source
 Reprogrammable from somatic cells
 Possibility of generating patient-speciﬁc donor cells
for autologous transplantation
 Reduced probability of immune rejection
 No ethical concerns
 Derived DAergic neurons have shown to survive and
induce functional beneﬁts in PD animals
 Differentiation pattern variability in vivo
 Risk for teratoma formation
 Autologous transplantation: risk of
susceptibility for the original pathology, related
with possible genetic mutations present in
patients ﬁbroblasts
 No data in non-human primate models of PD
Hargus et al. (2010), Politis and Lindvall (2012b),
Swistowski et al. (2010) and Wernig et al. (2008)
MSCs  Easy to isolate, expandable in culture and great
proliferative potential with minimal senescence
through multiple passages
 Isolated from different tissue sources
 Obtained with minimal invasive procedures
 Safe source for autologous transplantation
 Possess immunosuppressive function
 Secrete a vast panel of growth factors and cytokines
 Less prone for tumor formation
 Not hindered by ethical concerns
 Undifferentiated MSCs have shown not only to
survive and migrate toward the injured site and to
promote neuroregeneration in PD animals, but also to
ameliorate animals’ motor deﬁcits through the
secretion of bioactive molecules
 Full differentiation of MSCs-derived DAergic
neurons remains to be proven
 No data on undifferentiated MSCs
transplantation in non-human primate models
of PD
 Transplantation of BMSCs provided only
modest clinical improvement in humans
Blandini et al. (2010), Bouchez et al. (2008), Cova et al.
(2010), Hayashi et al. (2013), Kim et al. (2009), Kishk
and Abokrysha (2011), Levy et al. (2008), McCoy et al.
(2008), Offen et al. (2007), Park et al. (2012), Sadan
et al. (2009), Salgado et al. (2006), Shetty et al. (2009),
Teixeira et al. (2013), Venkataramana et al. (2010),
Wang et al. (2010), Wang et al. (2013), Weiss et al.
(2006), and Zhou et al. (2013a)
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or cells induced the recovery of motor functions, which was
associated with graft-derived reinnervation of most of the
caudate-putamen. Subsequent studies consistently demonstrated
that intrastriatal transplantation of rat fetal SN tissue could
reinnervate rat striatum, secrete DA and induce substantial, or
even complete, reversion of motor deﬁcits (Björklund and
Kordower, 2013; Dunnett et al., 1983, 1988; Koller, 2003). The
extent of the animals’ motor recovery largely depended on the
extent of nigrostriatal reinnervation and DA restoration following
SN transplants. Thus, the observation that animal's behavioral
recovery could only be achieved with striatal intra-parenchyma
grafting led to the abandonment of intraventricular transplanta-
tion (Björklund and Kordower, 2013). In the late 1980s, the ﬁrst
human open trials were performed and revealed promising results
on the long-term survival of DAergic neurons as well as DA
synthesis, following human FVM tissue transplantation (Hagell
et al.,1999; Koller, 2003; Kordower et al.,1996; Lindvall et al.,1990;
Wenning et al., 1997; Widner et al., 1992). Motivated by these
encouraging results, two National Institute of Health funded
double-blind placebo-controlled trials were conducted in ad-
vanced PD patients (Freed et al., 2001; Olanow et al., 2003).
However, both studies failed to meet their primary outcome
concerning long-term survival of DAergic neurons and some
patients developed severe graft-induced dyskinetic side effects
postoperatively. In addition, Lewy bodies degeneration was
observed in the patients that have been examined post-mortem,
ten to sixteen years after human FVM tissue transplantation
(Kordower et al., 2008; Li et al., 2008; Rascol et al., 2011). Moreover,methodological and ethics related issues associated with human
FVM tissue harvesting have also hindered its use in PD therapeutics
(Azari et al., 2010; Teixeira et al., 2013). Nevertheless, the reported
improvement in striatal DAergic neurons and functional outcome
in some patients with PD resulted in a currently ongoing phase I
European clinical trial (TRANSEURO – NCT01898390). For this trial,
an optimized tissue preparation protocol to reduce the graft-
induced dyskinesias has been applied.
5.2. Embryonic stem cells
Embryonic stem (ES) cells are derived from the inner cell mass
of the blastocyst. They are considered to be pluripotent cells due to
their capability to differentiate into the three germ layers
(endoderm, mesoderm and ectoderm) of the embryo (Salgado
et al., 2006). ES cells are highly proliferative cells, able to maintain
their pluripotency for long periods of in vitro expansion (Politis and
Lindvall, 2012a). The possibility of establishing large-scale
production of ES cells and to differentiate them into DAergic
neurons, led to the possibility of these cells being considered as a
tool for generating new cell-based PD therapeutic protocols (Cho
et al., 2008; Park et al., 2004; Perrier et al., 2004). Numerous animal
experiments using either rodent or human ES cells-derived
dopaminergic neurons showed that these cells could induce
functional recovery in animal models of PD (Ben-Hur et al., 2004;
Björklund et al., 2002; Brederlau et al., 2006; Kim et al., 2002; Yang
et al., 2008b). Indeed, Björklund et al. and Kim et al., demonstrated
that striatal grafted ES cells-derived DAergic neurons were able to
survive, integrate and reinnervate the striatum, and this way
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2002). Björklund at al. (2002) also observed that the degree of
striatal reinnervation was correlated with animals’ behavior
improvement, an observation that has again been reported by
Yang and colleagues (Yang et al., 2008b). However, despite the
consistent description of animals’ motor improvement following
ES cells-derived DAergic neurons grafting, phenotypic instability of
the grafts and consequent tumor formation in rats has also been
reported (Brederlau et al., 2006; Roy et al., 2006). Therefore, issues
related with safety and ES cells inappropriate differentiation into
midbrain neurons have severely hampered its clinical application.
Kriks et al. (2011) has recently readdressed these concerns, which
might bring back ES cells into the clinical arena. Still, human ES
cells use in clinics is surrounded by controversy related with
possible immune rejection of the grafts as well as with safety and
ethical issues.
5.3. Neural stem cells
Neural stem/precursor cells (NSCs) are multipotent cells,
capable of differentiating into the main phenotypes of the central
nervous system, namely neurons, astrocytes and oligodendrocytes
(Yi et al., 2013). NSCs can be isolated from developing or adult
central nervous system tissue (Bennett et al., 2009; Meyer et al.,
2010) and cultured in vitro as free-ﬂoating spheres (neurospheres)
in the presence of endothelium growth factor and/or basic
ﬁbroblast growth factor (Bonnamain et al., 2012). Their intrinsic
properties, and the prospect of using them for replacement of lost
DAergic neurons and reconstitution of the DAergic transmission,
raised great interest in the use of NSCs as a source for cell
replacement therapy in PD.
The ﬁrst studies using undifferentiated embryonic or fetal NSCs,
isolated from cortical and midbrain areas of rodent developing
brain, not only reported poor survival and differentiation of striatal
grafted cells into DAergic neurons in animal models of PD, but also
only mild amelioration of lesion induction deﬁcits (Svendsen et al.,
1997; Svendsen et al., 1996). In addition, these and other studies
have consistently reported that only NSCs isolated from the
midbrain could differentiate into DAergic neurons (Meyer et al.,
2010; Sanchez-Pernaute et al., 2001; Storch et al., 2001, 2004).
Since then most transplantation studies use either rodent (Carvey
et al., 2001; Sawamoto et al., 2001; Schwarz et al., 2006) or human
fetal NSCs (Sanchez-Pernaute et al., 2001) differentiated into
DAergic neurons in vitro prior to transplantation. These studies
showed that striatal transplantation of fetal NSCs-derived DAergic
neurons resulted in histological, biochemical and functional
recovery in animal models of PD. Moreover, one of these studies
reported NSCs to have a milder immune rejection and lower risk of
tumor formation than ES cells (Schwarz et al., 2006). However,
despite these encouraging results, a low percentage of the
transplanted cells survived and/or adopted the DAergic phenotype
in vivo after both short- and long-term in vitro expansion of NSCs
(Carvey et al., 2001; Sawamoto et al., 2001; Schwarz et al., 2006).
These results, together with the mild-beneﬁts observed in the
functional recovery of PD animals reported in earlier studies
(Svendsen et al., 1997, 1996), have been associated with NSCs
dependence on developmental signals (e.g., ﬁbroblast growth
factor 8 and Sonic hedgehog) and transcription factors (e.g., nuclear
receptor realated-1 protein) (Storch et al., 2004) implicated in
DAergic neurons development (Perrone-Capano and Di Porzio,
2000; Storch et al., 2004). Parish et al. proposed that an alternative
method to address this issue was through the culture of genetically
engineered NSCs cells, together with developmental signals
necessary for inducing DAergic neurons differentiation in vivo
(Parish et al., 2008). Using this alternative method, the generation
of higher yields of functional DAergic neurons in vitro, along withan enhancement in TH-positive cells engraftment and in striatal
reinnervation in vivo, was obtained. These improvements were
followed by complete behavior recovery of parkinsonian rodents,
without tumor formation (Parish et al., 2008). Nevertheless, long-
term follow up of the animals should be provided in order to
ensure safety of these engineered cells. Despite the progresses
achieved with mesencephalic derived NSCs, the long-term survival
and phenotype stability of grafted DAergic neurons in animal
models of PD still remains to be demonstrated. Therefore,
standardization of protocols ensuring the control of NSCs
differentiation into homogeneous populations of DAergic neurons
should be established and their transplantation effects in
parkinsonian models must be further explored.
5.4. Induced pluripotent stem cells
Induced pluripotent stem cells (iPSCs) recently emerged in the
ﬁeld of regenerative medicine, following the pioneer studies
provided by Takahashi and colleagues (Takahashi et al., 2007;
Takahashi and Yamanaka, 2006) in which the authors showed that
ﬁbroblasts derived from mice or humans could be re-programmed
into pluripotent stem cells. These studies demonstrated that iPS
cells presented morphological and phenotypical properties similar
to ES cells, particularly pluripotency and generation of viable
chimeras (Brundin et al., 2010; Takahashi et al., 2007; Takahashi
and Yamanaka, 2006). Subsequent studies showed that iPS cells
not only exhibited genomic stability and transcription proﬁles
similar to ES cells, but were also able to use the same
transcriptional network and developmental patterning cues as
them to differentiate into DAergic neurons (Brundin et al., 2010;
Gibson et al., 2012; Swistowski et al., 2010; Wernig et al., 2008). In
reality, these cells can hold advantages over ES cells, such as the
possibility of generating patient speciﬁc donor cells for autologous
transplantation and this way avoid both immune rejection and
ethical concerns related with the use of ES cells (Wernig et al.,
2008).
Studies on transplantation of iPS cells into the striatum of PD
animals, either obtained from mice or PD patients somatic cells,
provided proof-of-principle for their ability to survive and induce
functional beneﬁts in PD animals (Hargus et al., 2010; Swistowski
et al., 2010; Wernig et al., 2008). However, these studies also
reported variability in the differentiation pattern of iPS cells into
DAergic neurons in vivo. It has also been observed that tumor
(teratoma) formation can occur if iPS cells grafts are not fully
differentiated prior to transplantation (Wernig et al., 2008).
Moreover, DAergic neurons differentiated from patient-derived
iPSCs exhibit a remarkable reduction in the number of neurites and
an increased accumulation of autophagic vacuoles when compared
to DAergic neurons derived from iPSCs of healthy controls
(Sanchez-Danes et al., 2012).
5.5. Induced neural cells
In an attempt to address the complications related with
incomplete and unsynchronized differentiation of iPS cells
observed in vivo (Hargus et al., 2010; Wernig et al., 2008), an
interesting alternative approach, consisting in directly reprogram-
ing one somatic cell type into another, was proposed some years
ago by Melton and colleagues (Zhou et al., 2008). Vierbuchen et al.
have also reprogrammed ﬁbroblasts into functional neurons in
vitro using a similar combinatorial strategy of three neural-speciﬁc
transcription factors (Brundin et al., 2010; Vierbuchen et al., 2010).
The resulting cells were named induced neural cells (iN cells).
These cells have shown the capability to generate DAergic neurons
in vitro, while avoiding the reversion to a pluripotent stage,
therefore diminishing the risk for tumor formation. However, the
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on PD animals’ phenotype remains to be demonstrated (Caiazzo
et al., 2011; Gibson et al., 2012; Pﬁsterer et al., 2011).
5.6. Mesenchymal stem cells
Mesenchymal stem/stromal cells (MSCs) were initially reported
by Friedenstein and colleagues, that deﬁned cells isolated from
bone marrow as plastic-adherent ﬁbroblast colony-forming units
with clonogenic capacity (Friedenstein et al., 1974). These cells
were named in 1991 as marrow “stromal cells” by Eaves et al.,
based on their possible use as a feeder layer for hematopoietic stem
cells (Eaves et al., 1991). In that same year, these cells also became
known as mesenchymal stem cells on the basis of the report on
their clonogenicity and ability to undergo multilineage differenti-
ation, published by Caplan and colleagues (Caplan,1991). Currently
MSCs are deﬁned, according with the International Society for
Cellular Therapy criteria, as multipotent cells, capable of self-
renewal and of differentiating into adipocytes, osteoblasts and
chondroblasts (Emsley et al., 2005). Additionally, MSCs have also
been characterized by their ability to adhere to tissue culture
plastic and to display the presence of cells surface markers (CD105,
CD73, CD90), as well as the lack of hematopoietic cell surface
markers (CD45, CD34, CD14 or CD11b, CD79a or CD19 and Human
Leukocyte Antigen DR) (Dominici et al., 2006). So far, MSCs have
been isolated from bone marrow (BMSCs), adipose tissue (ASCs),
dental pulp, placenta, amniotic ﬂuid, umbilical cord blood,
umbilical cord Wharton's jelly (WJ-MSCs/HUCPVCs), liver, lung
and spleen (Teixeira et al., 2013). They have been reported to be
isolated with minimal invasive procedures; easily cultured and
expanded in vitro for several passages; used for autologous
transplantation in virtue of their hypo-immunogenicity (probably
related with their surface expression of major histocompatibility
complex antigens); have less probability of being tumorigenic and,
as adult cells, not hindered by ethical concerns (Kishk and
Abokrysha, 2011; Salgado et al., 2006; Seo and Cho, 2012; Teixeira
et al., 2013). These features have made MSCs attractive tools for
tackling central nervous system neurodegenerative diseases.
Indeed, a considerable body of evidence has revealed the potential
of such cells to promote protection and/or recovery of DAergic
neurons, against neurotoxin-induced nigrostriatal degeneration,
following intrastriatal (Blandini et al., 2010; Bouchez et al., 2008;
Cova et al., 2010; Khoo et al., 2011; McCoy et al., 2008; Sadan et al.,
2009; Weiss et al., 2006) intranigral (Mathieu et al., 2012; Somoza
et al., 2010), intrathecal (Salama et al., 2012) intravenous (Chao
et al., 2009; Wang et al., 2010) and intranasal (Danielyan et al.,
2011) delivery of BMSCs, ASCs or WJ-MSCs in rodent or non-human
primate models of PD. The mechanisms underlying in vivo
functional recovery following MSCs transplantation are, however,
a matter of intense debate.
Several groups have focused on the application of MSCs as
replacers of injured DAergic neurons, using neuronal-induced
MSCs – prior to transplantation – in PD animal models (Baer and
Geiger, 2012; Hermann et al., 2004; Jiang et al., 2002; Mitchell
et al., 2003; Munoz-Elias et al., 2004; Phinney and Prockop, 2007).
Indeed, several authors have reported that BMSCs-, ASCs- and WJ-
MSCs-derived DAergic neurons transplantation into the striatum,
of both rodent and primate models of PD, survived for long periods
and increased the levels of DAergic markers. Motor improvement
was also described (Hayashi et al., 2013; Levy et al., 2008; Offen
et al., 2007; Shetty et al., 2009; Wang et al., 2013; Zhou et al.,
2013a). In addition, two of these studies have reported detectable
levels of DA in culture medium following in vitro BMSCs
differentiation into DAergic phenotype or DA release after
depolarization by potassium stimulation (Hayashi et al., 2013;
Shetty et al., 2009). Similar outcomes were also described afterintranigral transplantation of undifferentiated WJ-MSCs and WJ-
derived DAergic neurons in a 6-OHDA rodent model of PD (Shetty
et al., 2013). In this study, the authors further compared the effect
of either naïve or differentiated BMSCs and WJ-MSCs in parkinso-
nian animals. Results revealed that, both naïve and differentiated
WJ-MSCs were able to signiﬁcantly improve the motor behavior,
although this effect was more striking in differentiated WJ-MSCs
transplanted animals. In contrast, Bouchez et al. reported similar
beneﬁcial effects on animals’ behavioral recovery after intrastriatal
transplantation of either BMSCs cultured in standard conditions or
in neuronal differentiation medium (Bouchez et al., 2008). On the
other hand, McCoy et al. showed that ASCs were able to protect
DAergic neurons and ameliorate animals’ functional deﬁcits
against neurotoxin-induced neurodegeneration, without the need
of DAergic differentiation (McCoy et al., 2008). Comparable to what
Bouchez et al. and McCoy et al. found, other researchers have
reported no in vivo differentiation of in vitro neural-induced MSCs
(Chao et al., 2009; Khoo et al., 2011), after intrastriatal or
intravenous transplantation in 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) and 6-OHDA rodent models of PD. Also, robust
data failed to provide robust evidence regarding MSCs differentia-
tion into full functional neurons (Liu et al., 2012; Thomas et al.,
2011; Trzaska et al., 2007). Therefore, it seems unlikely that MSCs
differentiation into neuronal lineages is the major contributor for
MSCs-induced recovery in PD.
In recent years, MSCs regenerative effects have been related to
their secretome, that is, to the panel of bioactive soluble factors and
vesicles with neuroregulatory properties released by these cells to
the extracellular environment (Teixeira et al., 2013). Different
tissue derived MSCs not only seem to sense local environment, but
have also shown to respond to signals that are up-regulated under
injury conditions by migrating to the damage site. Once there, they
promote cell regeneration and limit the extent of tissue damage
through the secretion of soluble growth factors (GFs), anti-
inﬂammatory cytokines and microvesicles/exosomes (Caplan
and Dennis, 2006; Ding et al., 2007; Li et al., 2002; Meirelles
Lda et al., 2009; Neuhuber et al., 2005; Yang et al., 2008a). The
effect of these soluble factors can be generally classiﬁed into
neuroprotective/anti-apoptotic, neurogenic, angiogenic and syn-
aptogenic. Such effects are commonly mediated by the secretion of
the following factors by MSCs (Chen et al., 2000, 2001a,b; Ding
et al., 2007; Hu et al., 2010; Li et al., 2002; Lin et al., 2011; Lopatina
et al., 2011; Neuhuber et al., 2005; Wakabayashi et al., 2010; Wei
et al., 2009; Wright et al., 2007): brain-derived neurotrophic factor
(BDNF), GDNF, nerve growth factor, hepatocyte growth factor,
vascular endothelial growth factor, vascular endothelial growth
factor receptor 3, angiopoietin 1, insulin-like growth factor 1,
insulin-like growth factor 2, endothelium growth factor, basic
ﬁbroblast growth factor, ﬁbroblast growth factor 20, granulocyte
colony-stimulating factor, platelet-derived growth factor AA,
chemokine ligand 16, neutrophil-activating-protein-2 and neuro-
trophin-3 growth factors, as well as interleukin-6, interleukin-10,
transforming growth factor beta 1, stem cell factor, stromal cell-
derived factor 1 and monocyte chemotactic protein 1 cytokines.
In the context of PD, several studies have also demonstrated
that BMSCs secretome has a protective and/or regenerative
character on DAergic neurons in in vitro and in vivo models of
PD (Blandini et al., 2010; Cova et al., 2010; Danielyan et al., 2011;
Kim et al., 2009; McCoy et al., 2008; Park et al., 2012; Sadan et al.,
2009; Shintani et al., 2007; Wang et al., 2010; Weiss et al., 2006).
For instance, Shintani and coworkers demonstrated that BMSCs
conditioned media was able to promote survival of TH-positive
DAergic neurons in rat primary cultures of ventral mesencephalic
cells (Shintani et al., 2007). Moreover, intrastriatal transplantation
of fetal mesenchephalic cells, pre-treated with human BMSCs
conditioned media, induced survival of DAergic grafted cells and
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(Shintani et al., 2007). The observed protection of DAergic neurons
was attributed to BMSCs secretion of BDNF, GDNF and basic
ﬁbroblast growth factor, all of which had previously shown to
stimulate survival of DAergic neurons (Shintani et al., 2007;
Teixeira et al., 2013). Similarly, Sadan et al. showed not only that
human BMSCs cultured in the presence of growth factors
signiﬁcantly increased the viability of the SH-SY5Y neuroblastoma
cell line exposed to 6-OHDA, but also that BMSCs transplanted into
the striatum of a 6-OHDA rat model of PD migrated to the lesion
site, increased the number of TH-positive cells and the DA levels
(Sadan et al., 2009). These neuroprotective and neuro-regenerative
effects were accompanied by a reversion of behavioral impair-
ments and were correlated with BMSCs secretion of signiﬁcant
amounts of BDNF and GDNF. Likewise, this expression pattern is in
accordance with data published by Blandini and colleagues using
the same animal model (Blandini et al., 2010). On the other hand,
Wang and colleagues associated rat-derived BMSCs expression of
stromal cell-derived factor 1a with DAergic neurons protection
against 6-OHDA neurotoxin, both in vitro and in vivo, through anti-
apoptotic based mechanisms (Wang et al., 2010). Moreover, Cova
et al. demonstrated that human BMSCs transplanted into the
striatum of a 6-OHDA rodent model of PD were able to survive and
interact with the lesion site surroundings, thus enhancing survival
of DAergic terminals and neurogenesis in the SVZ in a sustained
manner (Cova et al., 2010). Importantly, BMSCs in vitro secretion of
neurogenic (endothelium growth factor, neurotrophin-3, BDNF),
neurodevelopmental, neurorescuing and lesion home-mediating
GFs (vascular endothelial growth factor, hepatocyte growth factor,
basic ﬁbroblast growth factor), along with the active secretion of
BDNF in vivo, were correlated with the activation of endogenous
stem cells and striatal/nigral DAergic protection against neuro-
degeneration induced by 6-OHDA (Cova et al., 2010). Similarly, Park
et al., using a MPTP mice model of PD, reported that BMSCs were
able to modulate neurogenesis through the production of
endothelium growth factor (Park et al., 2012).
In addition to the capability of BMSCs to induce survival and
restorative effects on DAergic neurons, they also present immu-
nomodulatory and anti-inﬂammatory properties. In this context,
Danielyan and coworkers recently showed that intranasally
delivered rat BMSCs to 6-OHDA exposed rats migrated toward
the SN and the striatum, and prevented the decrease of DA in
lesioned brain areas (Danielyan et al., 2011). Moreover, a
substantial improvement of animals’ motor function was also
observed. These neuroprotective effects and functional recovery of
the DAergic system have been associated with the increase of BDNF
levels in the lesioned hemisphere side as well as with the BMSCs
capacity to modulate the host immune response and exert a strong
anti-inﬂammatory activity. Indeed, MSCs are known to modulate
the response of inﬂammatory cells by decreasing the expression of
pro-inﬂammatory cytokines, such as interleukin 1b, interleukin 2,
interleukin 12, tumor necrosis factor a and interferon g (Danielyan
et al., 2011; Meirelles Lda et al., 2009). The secretion of interleukin-
6, interleukin-10 and transforming growth factor b anti-inﬂam-
matory cytokines by BMSCs was also related with the protection of
nigral DAergic neurons, by other authors (Kim et al., 2009).
Some other studies have also demonstrated that ASCs and WJ-
MSCs secretome induces DAergic neurons survival in 6-OHDA
models of PD, as well as an improvement in animals’ motor
impairments (McCoy et al., 2008; Weiss et al., 2006). For instance,
Weiss et al. showed that WJ-MSCs transplantation in a 6-OHDA
model of PD could increase the number of TH-positive cells and
ameliorate PD animal behavior through the secretion of GDNF and
ﬁbroblast growth factor 20 (Weiss et al., 2006). Using the same
animal model, McCoy et al. also demonstrated that intranigral
transplantation of ASCs increased both the survival and protectionof DAergic neurons in the lesioned area and ameliorated animals’
motor deﬁcits through the secretion of nerve growth factor, BDNF
and GDNF (McCoy et al., 2008). The same authors also observed
that ASCs attenuated microglial activation in the lesioned SNpc and
suggested that this capacity to modulate microglial activity could
be related with ASCs secretion of anti-inﬂamatory molecular
mediators (McCoy et al., 2008).
From the above referred studies, it is clear that there is
increasing evidence indicating that the neuroprotective and
neuroregenerative effects of MSCs observed in PD are attributed
to the secretion of soluble GFs and cytokines. MSCs secretion of
these factors not only protects DAergic neurons from further
degeneration and enhances endogenous reparative processes (e.g.,
neurogenesis), but also acts as inﬂammation and immune
response modulator. Moreover, recent reports have shown that
besides soluble GFs and cytokines, MSCs also secrete microvesicles
and exosomes containing miRNA, which are believed to mediate
cell-to-cell communication and act as reparative agents (Baglio
et al., 2012; Zhou et al., 2013b; Zhu et al., 2013). Indeed, Xin et al.
have already demonstrated in vitro that exosomes secreted by
BMSCs not only mediate communication with neurons and
astrocytes, but could regulate neurite outgrowth by transferring
miRNA (miR-133b) to neural cells (Xin et al., 2012).
6. Future perspectives
As reviewed by Onofrj and colleagues (Onofrj et al., 2008),
satisfactory approaches that slow down PD, by protecting DAergic
neurons from premature death, are missing.
As it was already described, the current symptomatic treatment
relies in the reestablishment of dopamine levels through the use of
L-DOPA, DA agonists (e.g., ropinirole or pramipexole), MAO-B (e.g.,
rasagiline or selegiline) and COMT (e.g., entacapone or tolcapone)
inhibitors, to compensate its deﬁcits in the nigrostriatal dopami-
nergic pathway. Although efﬁcacious, these molecules cannot
induce the recovery of lost DAergic neurons or to protect those that
have not yet been impacted by the disease (Onofrj et al., 2008).
Moreover, it is nowadays accepted that several other factors
contribute to PD progression besides DA deﬁcits in the nigrostriatal
pathway namely, mitochondrial dysfunction, reactive oxygen
species, ubiquitination, proteasomal dysfunction and neuroin-
ﬂammation (Yadav et al., 2014). This way, some questions should
be raised: will there be alternative strategies to L-DOPA? Can we
combine the use of L-DOPA with other therapeutic strategies to
improve its action, and reduce side effects and dosages? Such
questions represent at the present time one of the major
challenges of PD research.
Saﬁnamide ((S)-(+)-2-[4-(3-ﬂuorbenzyloxybenzylamino)pro-
panamide]methanesulfonate), a MAO-B inhibitor and a blocker
of N-methyl-D-aspartate glutamate receptor (NMDAR) and sodi-
um/calcium channels, has been presented as a promising
therapeutic option for PD (Perez-Lloret and Rascol, 2016). Recently
licensed by European Medicines Agency (EMA) as an “add-on”
therapy, it has been described as an enhancer of dopaminergic
transmission, presenting decreased secondary effects when
compared to L-DOPA (Fabbri et al., 2015; Stocchi and Torti,
2016). In addition, neuroprotective effects have also been
attributed to saﬁnamide, preventing/inhibiting the formation of
toxins or free radicals by oxidative stress and glutamate/gamma-
aminobutyric acid (GABA) release, thereby reducing the excitotoxic
input in DAergic neuronal death (Perez-Lloret and Rascol, 2016).
From the application point of view, saﬁnamide has already
demonstrated to have a high oral bioavailability, presenting
satisfactory levels of safety, tolerability and efﬁcacy both in pre-
clinical and clinical assays (Caccia et al., 2006; Fabbri et al., 2015).
For instance, when compared to other MAO-B inhibitors like
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exhibiting a highly selective and reversible MAO-B inhibition, with
a level of selectivity for MAO-B clearly superior to the above
referred drugs (Caccia et al., 2006). Such evidence represents a
crucial advantage, particularly for patients who experience
adverse effects and need to be treated with other drugs, in which
case the reversibility of saﬁnamide avoids potential drug
interactions. Also, when saﬁnamide was added to a single DA
agonist, a superior beneﬁt was achieved (Stocchi et al., 2004). Even
when combined with the standard treatment L-DOPA, saﬁnamide
was able to signiﬁcantly increase its availability in the serum. This
result suggests that such effect is accomplished by saﬁnamide
itself, due to the putative inhibition of DA reuptake through MAO-B
inhibition and not due to the inhibition of metabolizing enzymes,
such as dopadecarboxylase or catechol-O-methyltransferase
(COMT) (Onofrj et al., 2008). Despite these promising results, to
the best of our knowledge, there are no studies reporting the
effects of saﬁnamide in drug naïve patients and even in early stages
of PD (Cattaneo et al., 2016; Fabbri et al., 2015; Muller, 2016). Such
experiments could in the future open unprecedented opportu-
nities to change PD research and its therapeutic approaches.
Along the same line as saﬁnamide, there is opicapone, a novel,
once-daily and potent third-generation cathecol-O-methyltrans-
ferase inhibitor (Ferreira et al., 2015a; Scott, 2016). Recently
approved, oral opicapone is, like saﬁnamide, an adjunct therapy to
L-DOPA, to be used in adults with PD and end-of-dose motor
ﬂuctuations who cannot be stabilized (Devos and Moreau, 2015;
Scott, 2016). Described as a hydrophilic 1,2,4-oxadiazole analog
with pyridine N-oxide residue at position 3, this drug provides a
high COMT inhibitory action, without inducing relevant cytotoxic-
ity in cells (Kiss et al., 2010). Indeed, in pre-clinical models,
opicapone was found to prolong the inhibitory effect on peripheral
COMT and extend the bioavailability of L-DOPA, without inducing
toxicity (Bonifacio et al., 2015). Similarly, on Cynomolgous
monkeys, the referred drug was also found to not only increase
the systemic exposure to L-DOPA, but also to increase its levels in
the dorsal striatum and substantia nigra (Bonifacio et al., 2014).
Even from the clinical point of view, Ferreira and colleagues
(Ferreira et al., 2015b) demonstrated that opicapone signiﬁcantly
reduced COMT activity, increasing the systemic exposure to L-
DOPA, which translated in an improved motor response by the
patients, when compared to placebo. When it was applied in
healthy volunteers, a pronounced effect was also observed in
increasing L-DOPA bioavailability when compared to other COMT
inhibitor, such as entacapone (Rocha et al., 2014). More recently,
Ferreira and colleagues (Ferreira et al., 2015a) showed that a single
take (daily) of opicapone could enable a simpliﬁed drug regimen,
allowing for a decrease on the total daily L-DOPA dose and leading
to an increase of dose intervals, thereby reducing the number of
intakes and maximizing its beneﬁts. Such evidence opens
interesting new perspectives for PD treatment since, altogether,
data suggests opicapone to be a promising alternative to the
current available COMT inhibitors, simplifying PD drug regimens
and increasing patient's quality of life (Fabbri et al., 2016).
In addition to these two promising drugs, there are also some
new perspectives concerning DBS (Wichmann and DeLong, 2016).
Indeed, it has been claimed that understanding how DBS could
affect multiple cortical regions downstream, would be an
important advance in its use as a therapeutic approach (Alhourani
et al., 2015). Understanding also the network effects of DBS will
allow tailoring the treatment based on biomarkers related to those
effects. It is this way expected to achieve an increase on therapeutic
efﬁcacy and avoid undesirable side effects (Humphries and Gurney,
2012; Paek et al., 2015). Nevertheless, although promising, it still
has some limitations, namely the inability to (totally) recover/
protect DAergic neurons after PD onset. Therefore, the ﬁeld'scurrent view is that combinatory strategies may overcome the
limitations of single drug/surgical approaches, particularly by
combining them with stem cell-based strategies.
hMSCs secretome has recently been proposed as an alternative
therapeutic tool for PD, given its ability to modulate DAergic
neuronal survival (Teixeira et al., 2016a). In fact, using secretome as
a therapeutic approach, rather than transplanting cells, would be a
valuable tool in overcoming technical concerns associated to the
latter (e.g., number of cells needed and cell delivery). Recently it
has been demonstrated that hMSCs secretome can be successfully
modulated using dynamic culture conditions through computer-
controlled bioreactors (Teixeira et al., 2016b). Also, some studies
have shown that molecules secreted by hMSCs promote nervous
tissue regeneration through activation/modulation of endogenous
neuro-restorative processes. In the future, such molecules could be
an efﬁcacious add-on if combined with cell transplantation,
pharmacological or surgical strategies (Buttery and Barker, 2014;
Choi et al., 2010; Rowland et al., 2015; Yao et al., 2016). Although
most of the available results support hMSCs secretome as a
promising cell-free therapy and a potential off-the-shelf product for
PD, current sources of MSCs do not allow for the isolation of a
sufﬁcient number of cells for their widespread clinical use, instead
relying on invasive, expensive and labor–intense isolation proto-
cols that yield MSCs with limited proliferative capacity (Teixeira
et al., 2016b). Therefore, inducible pluripotent stem cells (iPSCs)
have been suggested as a possible alternative source for obtaining
large populations of MSC-like cells (iMSCs) (Jung et al., 2012; Kang
et al., 2015). In fact, the use of iPSCs as a new possible therapeutic
tool and also as a source of MSCs could be a breakthrough, since it
yields a more homogenous population of MSCs, and probably is
more robust in enhancing secretome production and potential. As
recently assumed by Lian and colleagues (Lian et al., 2010), the
greater potential of iPSCs and iMSCs may be related with their
ability to survive and proliferate longer whether in culture or after
transplantation, thereby being a more robust promising approach
than the classical adult MSCs. Thus, the establishment of patient-
speciﬁc iPSCs/iMSCs and their secretome could present an
unprecedented opportunity to change PD research, by redeﬁning
the disease in its molecular and cellular basis.
iPSCs have also been proposed as a promising in vitro model that
covers all the complexity of PD, allowing this way for research in
many, if not all, of the features of this pathogenesis, either from
sporadic or familial cases (Soldner et al., 2009). This approach may
also allow to predict (new) therapeutic outcomes for experimental
PD treatments, alone or in combination (e.g., PD drugs, DBS or
iMSCs/iPSCs secretome), as well as to track PD progression through
the identiﬁcation of new therapeutical targets. This way maybe
one day we might understand how to prevent or slow down
degeneration of DAergic neurons.
7. Conclusions
PD is the second most prevalent neurodegenerative disorder,
characterized by a variety of motor and non-motor features. With
the signiﬁcant advances made in the ﬁelds of etiology, pathobiol-
ogy and patho-anatomy of PD, new pharmacologic agents, gene
engineering and cell replacement therapeutic approaches have
been developed to meet the clinical challenge of treating or
modifying the course of the disease. Although important
progresses have been achieved, there are still important gaps
missing, particularly on better methods to induce regenerative
processes in the areas affected by the disease. In order to overcome
this, in the future it will be important to understand the true
potential of emerging technologies, such as those derived from
iPSC or MSCs secretome, as well as how these may be combined
with existing molecular and pharmacotherapies. Doing so, it will
A.O. Pires et al. / Progress in Neurobiology 156 (2017) 69–89 83be possible to tackle PD in a multi-dimensional and more effective
way.
Acknowledgments
Portuguese Foundation for Science and Technology (FCT) for the
PhD fellowship attributed to A.O. Pires (Reference: SFRH/BD/
33900/2009) and the IF development grant to A.J. Salgado
(Reference: IF/00111/2013). Project NORTE-01-0145-FEDER-
000013, supported by the Northern Portugal Regional Operational
Programme (NORTE 2020), under the Portugal 2020 Partnership
Agreement, through the European Regional Development Fund
(FEDER). Funded by FEDER funds, through the Competitiveness
Factors Operational Programme (COMPETE), and by National
funds, through the Foundation for Science and Technology (FCT),
under the scope of the project POCI-01-0145-FEDER-007038.
References
Ai, Y., Markesbery, W., Zhang, Z., Grondin, R., Elseberry, D., Gerhardt, G.A., Gash, D.
M., 2003. Intraputamenal infusion of GDNF in aged rhesus monkeys:
distribution and dopaminergic effects. J. Comp. Neurol. 461, 250–261.
Akao, Y., Maruyama, W., Yi, H., Shamoto-Nagai, M., Youdim, M.B., Naoi, M., 2002. An
anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline),
enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y
cells. Neurosci. Lett. 326, 105–108.
Alexander, G.E., Crutcher, M.D., DeLong, M.R., 1990. Basal ganglia-thalamocortical
circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic”
functions. Prog. Brain Res. 85, 119–146.
Alhourani, A., McDowell, M.M., Randazzo, M.J., Wozny, T.A., Kondylis, E.D., Lipski, W.
J., Beck, S., Karp, J.F., Ghuman, A.S., Richardson, R.M., 2015. Network effects of
deep brain stimulation. J. Neurophysiol. 114, 2105–2117.
Amalric, M., Lopez, S., Goudet, C., Fisone, G., Battaglia, G., Nicoletti, F., Pin, J.P., Acher,
F.C., 2013. Group III and subtype 4 metabotropic glutamate receptor agonists:
discovery and pathophysiological applications in Parkinson's disease.
Neuropharmacology 66, 53–64.
Anderson, V.C., Burchiel, K.J., Hogarth, P., Favre, J., Hammerstad, J.P., 2005. Pallidal vs
subthalamic nucleus deep brain stimulation in Parkinson disease. Arch. Neurol.
62, 554–560.
Aosaki, T., Miura, M., Suzuki, T., Nishimura, K., Masuda, M., 2010. Acetylcholine-
dopamine balance hypothesis in the striatum: an update. Geriatr. Gerontol. Int.
10 (Suppl. 1), S148–S157.
Azari, M.F., Mathias, L., Ozturk, E., Cram, D.S., Boyd, R.L., Petratos, S., 2010.
Mesenchymal stem cells for treatment of CNS injury. Curr. Neuropharmacol. 8,
316–323.
Aziz, T.Z., Peggs, D., Sambrook, M.A., Crossman, A.R., 1991. Lesion of the subthalamic
nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-induced parkinsonism in the primate. Mov. Disord. 6, 288–292.
Baer, P.C., Geiger, H., 2012. Adipose-derived mesenchymal stromal/stem cells: tissue
localization, characterization, and heterogeneity. Stem Cells Int. 2012, 1–11.
Baglio, S.R., Pegtel, D.M., Baldini, N., 2012. Mesenchymal stem cell secreted vesicles
provide novel opportunities in (stem) cell-free therapy. Front. Physiol. 3, 1–11.
Bankiewicz, K.S., Daadi, M., Pivirotto, P., Bringas, J., Sanftner, L., Cunningham, J.,
Forsayeth, J.R., Eberling, J.L., 2006. Focal striatal dopamine may potentiate
dyskinesias in parkinsonian monkeys. Exp. Neurol. 197, 363–372.
Bankiewicz, K.S., Eberling, J.L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J.,
Cunningham, J., Budinger, T.F., Harvey-White, J., 2000. Convection-enhanced
delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene
expression and restoration of dopaminergic function using pro-drug approach.
Exp. Neurol. 164, 2–14.
Bar Am, O., Amit, T., Youdim, M.B., 2004. Contrasting neuroprotective and
neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline
and selegiline. Neurosci. Lett. 355, 169–172.
Bartus, R.T., Herzog, C.D., Chu, Y., Wilson, A., Brown, L., Siffert, J., Johnson Jr., E.M.,
Olanow, C.W., Mufson, E.J., Kordower, J.H., 2011. Bioactivity of AAV2-neurturin
gene therapy (CERE-120): differences between Parkinson's disease and
nonhuman primate brains. Mov. Disord. 26, 27–36.
Battaglia, G., Busceti, C.L., Molinaro, G., Biagioni, F., Traﬁcante, A., Nicoletti, F., Bruno,
V., 2006. Pharmacological activation of mGlu4 metabotropic glutamate
receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine. J. Neurosci. 26, 7222–7229.
Beach, T.G., Adler, C.H., Sue, L.I., Peirce, J.B., Bachalakuri, J., Dalsing-Hernandez, J.E.,
Lue, L.F., Caviness, J.N., Connor, D.J., Sabbagh, M.N., Walker, D.G., 2008. Reduced
striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol.
115, 445–451.
Ben-Hur, T., Idelson, M., Khaner, H., Pera, M., Reinhartz, E., Itzik, A., Reubinoff, B.E.,
2004. Transplantation of human embryonic stem cell-derived neural
progenitors improves behavioral deﬁcit in Parkinsonian rats. Stem Cells 22,
1246–1255.Benabid, A.L., Chabardes, S., Mitrofanis, J., Pollak, P., 2009a. Deep brain stimulation
of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet
Neurol. 8, 67–81.
Benabid, A.L., Chabardes, S., Torres, N., Piallat, B., Krack, P., Fraix, V., Pollak, P., 2009b.
Functional neurosurgery for movement disorders: a historical perspective. Prog.
Brain Res. 175, 379–391.
Bennett, L., Yang, M., Enikolopov, G., Iacovitti, L., 2009. Circumventricular organs: a
novel site of neural stem cells in the adult brain. Mol. Cell. Neurosci. 41, 337–347.
Bennouar, K.E., Uberti, M.A., Melon, C., Bacolod, M.D., Jimenez, H.N., Cajina, M.,
Kerkerian-Le Goff, L., Doller, D., Gubellini, P., 2013. Synergy between L-DOPA and
a novel positive allosteric modulator of metabotropic glutamate receptor 4:
implications for Parkinson's disease treatment and dyskinesia.
Neuropharmacology 66, 158–169.
Benskey, M.J., Perez, R.G., Manfredsson, F.P., 2016. The contribution of alpha
synuclein to neuronal survival and function implications for Parkinson's
disease. J. Neurochem. 3, 331–359.
Bergman, H., Wichmann, T., DeLong, M.R., 1990. Reversal of experimental
parkinsonism by lesions of the subthalamic nucleus. Science 249, 1436–1438.
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., 1962. Behavior of monoamine
oxidase in the brain of man after therapy with monoamine oxidase inhibitors.
Wien. Klin. Wochenschr. 74, 558–559.
Betts, M.J., O’Neill, M.J., Duty, S., 2012. Allosteric modulation of the group III mGlu(4)
receptor provides functional neuroprotection in the 6-hydroxydopamine rat
model of Parkinson's disease. Br. J. Pharmacol. 166, 2317–2330.
Beurrier, C., Lopez, S., Revy, D., Selvam, C., Goudet, C., Lherondel, M., Gubellini, P.,
Kerkerian-LeGoff, L., Acher, F., Pin, J.P., Amalric, M., 2009. Electrophysiological
and behavioral evidence that modulation of metabotropic glutamate receptor 4
with a new agonist reverses experimental parkinsonism. FASEB J. 23, 3619–
3628.
Björklund, A., Kordower, J.H., 2013. Cell therapy for Parkinson's disease: what next?
Mov. Disord. 28, 110–115.
Björklund, A., Schmidt, R.H., Stenevi, U., 1980. Functional reinnervation of the
neostriatum in the adult rat by use of intraparenchymal grafting of dissociated
cell suspensions from the substantia nigra. Cell Tissue Res. 212, 39–45.
Björklund, L.M., Sanchez-Pernaute, R., Chung, S., Andersson, T., Chen, I.Y., McNaught,
K.S., Brownell, A.L., Jenkins, B.G., Wahlestedt, C., Kim, K.S., Isacson, O., 2002.
Embryonic stem cells develop into functional dopaminergic neurons after
transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. U. S. A. 99, 2344–
2349.
Björklund, T., Carlsson, T., Cederfjall, E.A., Carta, M., Kirik, D., 2010. Optimized adeno-
associated viral vector-mediated striatal DOPA delivery restores sensorimotor
function and prevents dyskinesias in a model of advanced Parkinson's disease.
Brain 133, 496–511.
Blandini, F., Cova, L., Armentero, M.T., Zennaro, E., Levandis, G., Bossolasco, P.,
Calzarossa, C., Mellone, M., Giuseppe, B., Deliliers, G.L., Polli, E., Nappi, G., Silani,
V., 2010. Transplantation of undifferentiated human mesenchymal stem cells
protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant.
19, 203–217.
Bonifacio, M.J., Sutcliffe, J.S., Torrao, L., Wright, L.C., Soares-da-Silva, P., 2014. Brain
and peripheral pharmacokinetics of levodopa in the cynomolgus monkey
following administration of opicapone, a third generation nitrocatechol COMT
inhibitor. Neuropharmacology 77, 334–341.
Bonifacio, M.J., Torrao, L., Loureiro, A.I., Palma, P.N., Wright, L.C., Soares-da-Silva, P.,
2015. Pharmacological proﬁle of opicapone, a third-generation nitrocatechol
catechol-O-methyl transferase inhibitor, in the rat. Br. J. Pharmacol. 172, 1739–
1752.
Bonnamain, V., Neveu, I., Naveilhan, P., 2012. Neural stem/progenitor cells as a
promising candidate for regenerative therapy of the central nervous system.
Front. Cell Neurosci. 6, 17.
Bouchez, G., Sensebe, L., Vourc’h, P., Garreau, L., Bodard, S., Rico, A., Guilloteau, D.,
Charbord, P., Besnard, J.C., Chalon, S., 2008. Partial recovery of dopaminergic
pathway after graft of adult mesenchymal stem cells in a rat model of
Parkinson's disease. Neurochem. Int. 52, 1332–1342.
Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., Braak, E., 2003a.
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol.
Aging 24, 197–211.
Braak, H., Rub, U., Gai, W.P., Del Tredici, K., 2003b. Idiopathic Parkinson's disease:
possible routes by which vulnerable neuronal types may be subject to
neuroinvasion by an unknown pathogen. J. Neural Transm. (Vienna) 110, 517–
536.
Bras, J.M., Singleton, A., 2009. Genetic susceptibility in Parkinson's disease. Biochim.
Biophys. Acta 1792, 597–603.
Brederlau, A., Correia, A.S., Anisimov, S.V., Elmi, M., Paul, G., Roybon, L., Morizane, A.,
Bergquist, F., Riebe, I., Nannmark, U., Carta, M., Hanse, E., Takahashi, J., Sasai, Y.,
Funa, K., Brundin, P., Eriksson, P.S., Li, J.Y., 2006. Transplantation of human
embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of
in vitro differentiation on graft survival and teratoma formation. Stem Cells 24,
1433–1440.
Brundin, P., Barker, R.A., Parmar, M., 2010. Neural grafting in Parkinson's disease
problems and possibilities. Prog. Brain Res. 184, 265–294.
Buttery, P.C., Barker, R.A., 2014. Treating Parkinson's disease in the 21st century: can
stem cell transplantation compete? J. Comp. Neurol. 522, 2802–2816.
Caccia, C., Maj, R., Calabresi, M., Maestroni, S., Faravelli, L., Curatolo, L., Salvati, P.,
Fariello, R.G., 2006. Saﬁnamide: from molecular targets to a new anti-Parkinson
drug. Neurology 67, S18–S23.
84 A.O. Pires et al. / Progress in Neurobiology 156 (2017) 69–89Caiazzo, M., Dell’Anno, M.T., Dvoretskova, E., Lazarevic, D., Taverna, S., Leo, D.,
Sotnikova, T.D., Menegon, A., Roncaglia, P., Colciago, G., Russo, G., Carninci, P.,
Pezzoli, G., Gainetdinov, R.R., Gustincich, S., Dityatev, A., Broccoli, V., 2011. Direct
generation of functional dopaminergic neurons from mouse and human
ﬁbroblasts. Nature 476, 224–227.
Caplan, A.I., 1991. Mesenchymal stem cells. J. Orthop. Res. 9, 641–650.
Caplan, A.I., Dennis, J.E., 2006. Mesenchymal stem cells as trophic mediators. J. Cell.
Biochem. 98, 1076–1084.
Cartmell, J., Schoepp, D.D., 2000. Regulation of neurotransmitter release by
metabotropic glutamate receptors. J. Neurochem. 75, 889–907.
Carvey, P.M., Ling, Z.D., Sortwell, C.E., Pitzer, M.R., McGuire, S.O., Storch, A., Collier, T.
J., 2001. A clonal line of mesencephalic progenitor cells converted to dopamine
neurons by hematopoietic cytokines: a source of cells for transplantation in
Parkinson's disease. Exp. Neurol. 171, 98–108.
Cattaneo, C., Sardina, M., Bonizzoni, E., 2016. Saﬁnamide as add-on therapy to
levodopa in mid- to late-stage Parkinson's disease ﬂuctuating patients: post hoc
analyses of studies 016 and SETTLE. J. Parkinsons Dis. 6, 165–173.
Celanire, S., Campo, B., 2012. Recent advances in the drug discovery of metabotropic
glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS
disorders. Expert Opin. Drug Discov. 7, 261–280.
Chao, Y.X., He, B.P., Tay, S.S., 2009. Mesenchymal stem cell transplantation
attenuates blood brain barrier damage and neuroinﬂammation and protects
dopaminergic neurons against MPTP toxicity in the substantia nigra in a model
of Parkinson's disease. J. Neuroimmunol. 216, 39–50.
Charcot, J.M., 2002. Policlinique du Mardi 31 Janvier. Charcot J-M Leçons du mardi à
la Saltpêtrière. La Bibliothèque des Introuvables, Paris, pp. 199–220.
Chen, J., Li, Y., Chopp, M., 2000. Intracerebral transplantation of bone marrow with
BDNF after MCAo in rat. Neuropharmacology 39, 711–716.
Chen, J., Li, Y., Wang, L., Zhang, Z., Lu, D., Lu, M., Chopp, M., 2001a. Therapeutic
beneﬁt of intravenous administration of bone marrow stromal cells after
cerebral ischemia in rats. Stroke 32, 1005–1011.
Chen, J., Sanberg, P.R., Li, Y., Wang, L., Lu, M., Willing, A.E., Sanchez-Ramos, J., Chopp,
M., 2001b. Intravenous administration of human umbilical cord blood reduces
behavioral deﬁcits after stroke in rats. Stroke 32, 2682–2688.
Chen, L., Ding, Y., Cagniard, B., Van Laar, A.D., Mortimer, A., Chi, W., Hastings, T.G.,
Kang, U.J., Zhuang, X., 2008. Unregulated cytosolic dopamine causes
neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28,
425–433.
Cheng, H.C., Ulane, C.M., Burke, R.E., 2010. Clinical progression in Parkinson disease
and the neurobiology of axons. Ann. Neurol. 67, 715–725.
Cho, M.S., Lee, Y.E., Kim, J.Y., Chung, S., Cho, Y.H., Kim, D.S., Kang, S.M., Lee, H., Kim, M.
H., Kim, J.H., Leem, J.W., Oh, S.K., Choi, Y.M., Hwang, D.Y., Chang, J.W., Kim, D.W.,
2008. Highly efﬁcient and large-scale generation of functional dopamine
neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 105,
3392–3397.
Choi, Y.J., Li, W.Y., Moon, G.J., Lee, P.H., Ahn, Y.H., Lee, G., Bang, O.Y., 2010. Enhancing
trophic support of mesenchymal stem cells by ex vivo treatment with trophic
factors. J. Neurol. Sci. 298, 28–34.
Christine, C.W., Starr, P.A., Larson, P.S., Eberling, J.L., Jagust, W.J., Hawkins, R.A.,
VanBrocklin, H.F., Wright, J.F., Bankiewicz, K.S., Aminoff, M.J., 2009. Safety and
tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology
73, 1662–1669.
Clark, J., Clore, E.L., Zheng, K., Adame, A., Masliah, E., Simon, D.K., 2010. Oral N-
acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein
overexpressing mice. PLoS ONE 5, e12333.
Connolly, B.S., Lang, A.E., 2014. Pharmacological treatment of Parkinson disease: a
review. JAMA 311, 1670–1683.
Cooper, I.S., 1973. Effect of chronic stimulation of anterior cerebellum on
neurological disease. Lancet 1, 206.
Coune, P.G., Schneider, B.L., Aebischer, P., 2012. Parkinson's disease: gene therapies.
Cold Spring Harb. Perspect. Med. 2, a009431.
Cova, L., Armentero, M.T., Zennaro, E., Calzarossa, C., Bossolasco, P., Busca, G.,
Lambertenghi Deliliers, G., Polli, E., Nappi, G., Silani, V., Blandini, F., 2010.
Multiple neurogenic and neurorescue effects of human mesenchymal stem cell
after transplantation in an experimental model of Parkinson's disease. Brain
Res. 1311, 12–27.
Cummins, G., Barker, R.A., 2012. What is the most promising treatment for
Parkinson's disease: genes, cells, growth factors or none of the above? Regen.
Med. 7, 617–621.
Cyr, M., Beaulieu, J.M., Laakso, A., Sotnikova, T.D., Yao, W.D., Bohn, L.M., Gainetdinov,
R.R., Caron, M.G., 2003. Sustained elevation of extracellular dopamine causes
motor dysfunction and selective degeneration of striatal GABAergic neurons.
Proc. Natl. Acad. Sci. U. S. A. 100, 11035–11040.
Danielyan, L., Schafer, R., von Ameln-Mayerhofer, A., Bernhard, F., Verleysdonk, S.,
Buadze, M., Lourhmati, A., Klopfer, T., Schaumann, F., Schmid, B., Koehle, C.,
Proksch, B., Weissert, R., Reichardt, H.M., van den Brandt, J., Buniatian, G.H.,
Schwab, M., Gleiter, C.H., Frey II, W.H., 2011. Therapeutic efﬁcacy of intranasally
delivered mesenchymal stem cells in a rat model of Parkinson disease.
Rejuvenation Res. 14, 3–16.
Dauer, W., Przedborski, S., 2003. Parkinson's disease: mechanisms and models.
Neuron 39, 889–909.
Dawson, T.M., Dawson, V.L., 2003. Molecular pathways of neurodegeneration in
Parkinson's disease. Science 302, 819–822.
Devos, D., Moreau, C., 2015. Opicapone for motor ﬂuctuations in Parkinson's disease.
Lancet Neurol..Dewey Jr., R.B., Hutton, J.T., LeWitt, P.A., Factor, S.A., 2001. A randomized, double-
blind, placebo-controlled trial of subcutaneously injected apomorphine for
parkinsonian off-state events. Arch. Neurol. 58, 1385–1392.
Dexter, D.T., Jenner, P., 2013. Parkinson disease: from pathology to molecular disease
mechanisms. Free Radic. Biol. Med. 62, 132–144.
Di Monte, D.A., 2003. The environment and Parkinson's disease: is the nigrostriatal
system preferentially targeted by neurotoxins? Lancet Neurol. 2, 531–538.
Dickson, D.W., Braak, H., Duda, J.E., Duyckaerts, C., Gasser, T., Halliday, G.M., Hardy, J.,
Leverenz, J.B., Del Tredici, K., Wszolek, Z.K., Litvan, I., 2009. Neuropathological
assessment of Parkinson's disease: reﬁning the diagnostic criteria. Lancet
Neurol. 8, 1150–1157.
Ding, D.C., Shyu, W.C., Chiang, M.F., Lin, S.Z., Chang, Y.C., Wang, H.J., Su, C.Y., Li, H.,
2007. Enhancement of neuroplasticity through upregulation of beta1-integrin
in human umbilical cord-derived stromal cell implanted stroke model.
Neurobiol. Dis. 27, 339–353.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D.,
Deans, R., Keating, A., Prockop, D., Horwitz, E., 2006. Minimal criteria for
deﬁning multipotent mesenchymal stromal cells. The International Society for
Cellular Therapy position statement. Cytotherapy 8, 315–317.
Dunkel, P., Chai, C.L., Sperlagh, B., Huleatt, P.B., Matyus, P., 2012. Clinical utility of
neuroprotective agents in neurodegenerative diseases: current status of drug
development for Alzheimer's, Parkinson's and Huntington's diseases, and
amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs 21, 1267–1308.
Dunnett, S.B., Bjorklund, A., Schmidt, R.H., Stenevi, U., Iversen, S.D., 1983.
Intracerebral grafting of neuronal cell suspensions. V. Behavioural recovery in
rats with bilateral 6-OHDA lesions following implantation of nigral cell
suspensions. Acta Physiol. Scand. Suppl. 522, 39–47.
Dunnett, S.B., Hernandez, T.D., Summerﬁeld, A., Jones, G.H., Arbuthnott, G., 1988.
Graft-derived recovery from 6-OHDA lesions: speciﬁcity of ventral
mesencephalic graft tissues. Exp. Brain Res. 71, 411–424.
Eaves, C.J., Cashman, J.D., Sutherland, H.J., Otsuka, T., Humphries, R.K., Hogge, D.E.,
Lansdorp, P.L., Eaves, A.C., 1991. Molecular analysis of primitive hematopoietic
cell proliferation control mechanisms. Ann. N. Y. Acad. Sci. 628, 298–306.
Eggert, D., Dash, P.K., Gorantla, S., Dou, H., Schiﬁtto, G., Maggirwar, S.B., Dewhurst, S.,
Poluektova, L., Gelbard, H.A., Gendelman, H.E., 2010. Neuroprotective activities
of CEP-1347 in models of neuroAIDS. J. Immunol. 184, 746–756.
Ehringer, H., Hornykiewicz, O., 1960. Verteilung von noradrenalin and dopamin im
gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen
systems. Klin. Wschr. 38, 1126–1239.
Ehringer, H., Hornykiewicz, O., 1998. Distribution of noradrenaline and dopamine
(3-hydroxytyramine) in the human brain and their behavior in diseases of the
extrapyramidal system. Parkinsonism Relat. Disord. 4, 53–57.
Emborg, M.E., Carbon, M., Holden, J.E., During, M.J., Ma, Y., Tang, C., Moirano, J.,
Fitzsimons, H., Roitberg, B.Z., Tuccar, E., Roberts, A., Kaplitt, M.G., Eidelberg, D.,
2007. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor
function and cortical metabolism. J. Cereb. Blood Flow Metab. 27, 501–509.
Emsley, J.G., Mitchell, B.D., Kempermann, G., Macklis, J.D., 2005. Adult neurogenesis
and repair of the adult CNS with neural progenitors, precursors, and stem cells.
Prog. Neurobiol. 75, 321–341.
Fabbri, M., Rosa, M.M., Abreu, D., Ferreira, J.J., 2015. Clinical pharmacology review of
saﬁnamide for the treatment of Parkinson's disease. Neurodegener. Dis. Manag.
5, 481–496.
Fabbri, M., Rosa, M.M., Ferreira, J.J., 2016. Clinical pharmacology review of opicapone
for the treatment of Parkinson's disease. Neurodegener. Dis. Manag. 6, 349–362.
Factor, S.A., 2008. Current status of symptomatic medical therapy in Parkinson's
disease. Neurotherapeutics 5, 164–180.
Parkinson's Disease Diagnosis and Clinical Management. In: Factor, S.A., Weiner, W.
J. (Eds.), Demos, New York.
Faggiani, E., Benazzouz, A., 2016. Deep brain stimulation of the subthalamic nucleus
in Parkinson's disease: from history to the interaction with the monoaminergic
systems. Prog. Neurobiol..
Fernandez, H.H., Chen, J.J., 2007. Monamine oxidase inhibitors: current and
emerging agents for Parkinson disease. Clin. Neuropharmacol. 30, 150–168.
Ferraye, M.U., Debu, B., Fraix, V., Goetz, L., Ardouin, C., Yelnik, J., Henry-Lagrange, C.,
Seigneuret, E., Piallat, B., Krack, P., Le Bas, J.F., Benabid, A.L., Chabardes, S., Pollak,
P., 2010. Effects of pedunculopontine nucleus area stimulation on gait disorders
in Parkinson's disease. Brain 133, 205–214.
Ferreira, J.J., Lees, A., Rocha, J.F., Poewe, W., Rascol, O., Soares-da-Silva, P., Bi-Park, i.,
2015a. Opicapone as an adjunct to levodopa in patients with Parkinson's disease
and end-of-dose motor ﬂuctuations: a randomised, double-blind, controlled
trial. Lancet Neurol..
Ferreira, J.J., Rascol, O., 2000. Prevention and therapeutic strategies for levodopa-
induced dyskinesias in Parkinson's disease. Curr. Opin. Neurol. 13, 431–436.
Ferreira, J.J., Rocha, J.F., Falcao, A., Santos, A., Pinto, R., Nunes, T., Soares-da-Silva, P.,
2015b. Effect of opicapone on levodopa pharmacokinetics, catechol-O-
methyltransferase activity and motor ﬂuctuations in patients with Parkinson's
disease. Eur. J. Neurol. 22, 815–825 e856.
Follett, K.A., Weaver, F.M., Stern, M., Hur, K., Harris, C.L., Luo, P., Marks Jr., W.J.,
Rothlind, J., Sagher, O., Moy, C., Pahwa, R., Burchiel, K., Hogarth, P., Lai, E.C., Duda,
J.E., Holloway, K., Samii, A., Horn, S., Bronstein, J.M., Stoner, G., Starr, P.A.,
Simpson, R., Baltuch, G., De Salles, A., Huang, G.D., Reda, D.J., 2010. Pallidal
versus subthalamic deep-brain stimulation for Parkinson's disease. N. Engl. J.
Med. 362, 2077–2091.
Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., Dillon, S.,
Winﬁeld, H., Culver, S., Trojanowski, J.Q., Eidelberg, D., Fahn, S., 2001.
A.O. Pires et al. / Progress in Neurobiology 156 (2017) 69–89 85Transplantation of embryonic dopamine neurons for severe Parkinson's disease.
N. Engl. J. Med. 344, 710–719.
Friedenstein, A.J., Chailakhyan, R.K., Latsinik, N.V., Panasyuk, A.F., Keiliss-Borok, I.V.,
1974. Stromal cells responsible for transferring the microenvironment of the
hemopoietic tissues. Cloning in vitro and retransplantation in vivo.
Transplantation 17, 331–340.
Gibson, S.A., Gao, G.D., McDonagh, K., Shen, S., 2012. Progress on stem cell research
towards the treatment of Parkinson's disease. Stem Cell Res. Ther. 3, 1–10.
Giladi, N., McDermott, M.P., Fahn, S., Przedborski, S., Jankovic, J., Stern, M., Tanner, C.,
2001. Freezing of gait in PD: prospective assessment in the DATATOP cohort.
Neurology 56, 1712–1721.
Gjerloff, T., Fedorova, T., Knudsen, K., Munk, O.L., Nahimi, A., Jacobsen, S., Danielsen,
E.H., Terkelsen, A.J., Hansen, J., Pavese, N., Brooks, D.J., Borghammer, P., 2015.
Imaging acetylcholinesterase density in peripheral organs in Parkinson's
disease with 11C-donepezil PET. Brain 138, 653–663.
Gjerstad, M.D., Alves, G., Wentzel-Larsen, T., Aarsland, D., Larsen, J.P., 2006.
Excessive daytime sleepiness in Parkinson disease: is it the drugs or the
disease? Neurology 67, 853–858.
Gjerstad, M.D., Wentzel-Larsen, T., Aarsland, D., Larsen, J.P., 2007. Insomnia in
Parkinson's disease: frequency and progression over time. J. Neurol. Neurosurg.
Psychiatry 78, 476–479.
Grondin, R., Cass, W.A., Zhang, Z., Stanford, J.A., Gash, D.M., Gerhardt, G.A., 2003.
Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine
release and motor speed in aged rhesus monkeys. J. Neurosci. 23, 1974–1980.
Grondin, R., Zhang, Z., Yi, A., Cass, W.A., Maswood, N., Andersen, A.H., Elsberry, D.D.,
Klein, M.C., Gerhardt, G.A., Gash, D.M., 2002. Chronic, controlled GDNF infusion
promotes structural and functional recovery in advanced parkinsonian
monkeys. Brain 125, 2191–2201.
Group, P.S., 2005a. A randomized placebo-controlled trial of rasagiline in levodopa-
treated patients with Parkinson disease and motor ﬂuctuations: the PRESTO
study. Arch. Neurol. 62, 241–248.
Group, T.P.S., 2005b. Safety and Efﬁcacy Study of CEP-1347 in the Treatment of
Parkinson's Disease. .
Hadaczek, P., Wu, G., Sharma, N., Ciesielska, A., Bankiewicz, K., Davidow, A.L., Lu, Z.
H., Forsayeth, J., Ledeen, R.W., 2015. GDNF signaling implemented by GM1
ganglioside; failure in Parkinson's disease and GM1-deﬁcient murine model.
Exp. Neurol. 263, 177–189.
Hagell, P., Schrag, A., Piccini, P., Jahanshahi, M., Brown, R., Rehncrona, S., Widner, H.,
Brundin, P., Rothwell, J.C., Odin, P., Wenning, G.K., Morrish, P., Gustavii, B.,
Bjorklund, A., Brooks, D.J., Marsden, C.D., Quinn, N.P., Lindvall, O., 1999.
Sequential bilateral transplantation in Parkinson's disease: effects of the second
graft. Brain 122, 1121–1132.
Hargus, G., Cooper, O., Deleidi, M., Levy, A., Lee, K., Marlow, E., Yow, A., Soldner, F.,
Hockemeyer, D., Hallett, P.J., Osborn, T., Jaenisch, R., Isacson, O., 2010.
Differentiated Parkinson patient-derived induced pluripotent stem cells grow
in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats.
Proc. Natl. Acad. Sci. U. S. A. 107, 15921–15926.
Harikrishna Reddy, D., Misra, S., Medhi, B., 2014. Advances in drug development for
Parkinson's disease: present status. Pharmacology 93, 260–271.
Hart, R.G., Pearce, L.A., Ravina, B.M., Yaltho, T.C., Marler, J.R., 2009. Neuroprotection
trials in Parkinson's disease: systematic review. Mov. Disord. 24, 647–654.
Hauser, R.A., 2011. Future treatments for Parkinson's disease: surﬁng the PD
pipeline. Int. J. Neurosci. 121 (Suppl. 2), 53–62.
Hayashi, T., Wakao, S., Kitada, M., Ose, T., Watabe, H., Kuroda, Y., Mitsunaga, K.,
Matsuse, D., Shigemoto, T., Ito, A., Ikeda, H., Fukuyama, H., Onoe, H., Tabata, Y.,
Dezawa, M., 2013. Autologous mesenchymal stem cell-derived dopaminergic
neurons function in parkinsonian macaques. J. Clin. Invest. 123, 272–284.
Heikkinen, H., Varhe, A., Laine, T., Puttonen, J., Kela, M., Kaakkola, S., Reinikainen, K.,
2002. Entacapone improves the availability of L-DOPA in plasma by decreasing
its peripheral metabolism independent of L-DOPA/carbidopa dose. Br. J. Clin.
Pharmacol. 54, 363–371.
Hely, M.A., Morris, J.G., Reid, W.G., Trafﬁcante, R., 2005. Sydney Multicenter Study of
Parkinson's disease: non-L-DOPA-responsive problems dominate at 15 years.
Mov. Disord. 20, 190–199.
Hermann, A., Gastl, R., Liebau, S., Popa, M.O., Fiedler, J., Boehm, B.O., Maisel, M.,
Lerche, H., Schwarz, J., Brenner, R., Storch, A., 2004. Efﬁcient generation of neural
stem cell-like cells from adult human bone marrow stromal cells. J. Cell Sci. 117,
4411–4422.
Herrero, M.T., Pérez-Otaño, I., Oset, C., Kastner, A., Hirsch, E.C., Agid, Y., Luquin, M.R.,
Obeso, J.A., Río, J.D., 1993. GM-1 ganglioside promotes the recovery of surviving
midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience 56
(4), 965–972.
Herzog, C.D., Dass, B., Gasmi, M., Bakay, R., Stansell, J.E., Tuszynski, M., Bankiewicz,
K., Chen, E.Y., Chu, Y., Bishop, K., Kordower, J.H., Bartus, R.T., 2008. Transgene
expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following
delivery to the monkey striatum. Mol. Ther. 16, 1737–1744.
Herzog, C.D., Dass, B., Holden, J.E., Stansell III, J., Gasmi, M., Tuszynski, M.H., Bartus,
R.T., Kordower, J.H., 2007. Striatal delivery of CERE-120, an AAV2 vector
encoding human neurturin, enhances activity of the dopaminergic nigrostriatal
system in aged monkeys. Mov. Disord. 22, 1124–1132.
Holmay, M.J., Terpstra, M., Coles, L.D., Mishra, U., Ahlskog, M., Oz, G., Cloyd, J.C., Tuite,
P.J., 2013. N-Acetylcysteine boosts brain and blood glutathione in Gaucher and
Parkinson diseases. Clin. Neuropharmacol. 36, 103–106.
Hu, S.L., Luo, H.S., Li, J.T., Xia, Y.Z., Li, L., Zhang, L.J., Meng, H., Cui, G.Y., Chen, Z., Wu, N.,
Lin, J.K., Zhu, G., Feng, H., 2010. Functional recovery in acute traumatic spinalcord injury after transplantation of human umbilical cord mesenchymal stem
cells. Crit. Care Med. 38, 2181–2189.
Humphries, M.D., Gurney, K., 2012. Network effects of subthalamic deep brain
stimulation drive a unique mixture of responses in basal ganglia output. Eur. J.
Neurosci. 36, 2240–2251.
Jankovic, J., 2008. Parkinson's disease: clinical features and diagnosis. J. Neurol.
Neurosurg. Psychiatry 79, 368–376.
Jankovic, J., Cardoso, F., Grossman, R.G., Hamilton, W.J., 1995. Outcome after
stereotactic thalamotomy for parkinsonian, essential, and other types of tremor.
Neurosurgery 37, 680–686 (discussion 686–687).
Jankovic, J., 2016. Movement disorders in 2016: Progress in Parkinson disease and
other movement disorders. Nat. Rev. Neurol. 13 (2), 76–78.
Jenner, P., 2003. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 (Suppl 3),
S26–S36 (discussion S36–28).
Jenner, P., 2004. Preclinical evidence for neuroprotection with monoamine oxidase-
B inhibitors in Parkinson's disease. Neurology 63, S13–S22.
Jenner, P., 2007. Oxidative stress and Parkinson's disease. Handb. Clin. Neurol. 83,
507–520.
Jiang, Y., Jahagirdar, B.N., Reinhardt, R.L., Schwartz, R.E., Keene, C.D., Ortiz-Gonzalez,
X.R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., Du, J., Aldrich, S., Lisberg, A.,
Low, W.C., Largaespada, D.A., Verfaillie, C.M., 2002. Pluripotency of
mesenchymal stem cells derived from adult marrow. Nature 418, 41–49.
Jost, W.H., Friede, M., Schnitker, J., 2012. Indirect meta-analysis of randomised
placebo-controlled clinical trials on rasagiline and selegiline in the
symptomatic treatment of Parkinson's disease. Basal Ganglia 2, S17–S26.
Jost, W.H., Friede, M., Schnitker, J., 2014. Comparative efﬁcacy of selegiline versus
rasagiline in the treatment of early Parkinson's disease. Eur. Rev. Med.
Pharmacol. Sci. 18, 3349.
Jung, Y., Bauer, G., Nolta, J.A., 2012. Concise review: induced pluripotent stem cell-
derived mesenchymal stem cells: progress toward safe clinical products. Stem
Cells 30, 42–47.
Kalia, L.V., Brotchie, J.M., Fox, S.H., 2013. Novel nondopaminergic targets for motor
features of Parkinson's disease: review of recent trials. Mov. Disord. 28,131–144.
Kalinderi, K., Fidani, L., Katsarou, Z., Bostantjopoulou, S., 2011. Pharmacological
treatment and the prospect of pharmacogenetics in Parkinson's disease. Int. J.
Clin. Pract. 65, 1289–1294.
Kang, R., Zhou, Y., Tan, S., Zhou, G., Aagaard, L., Xie, L., Bunger, C., Bolund, L., Luo, Y.,
2015. Mesenchymal stem cells derived from human induced pluripotent stem
cells retain adequate osteogenicity and chondrogenicity but less adipogenicity.
Stem Cell Res. Ther. 6, 144.
Kaplitt, M.G., Feigin, A., Tang, C., Fitzsimons, H.L., Mattis, P., Lawlor, P.A., Bland, R.J.,
Young, D., Strybing, K., Eidelberg, D., During, M.J., 2007. Safety and tolerability of
gene therapy with an adeno-associated virus (AAV) borne GAD gene for
Parkinson's disease: an open label, phase I trial. Lancet 369, 2097–2105.
Khoo, M.L., Tao, H., Meedeniya, A.C., Mackay-Sim, A., Ma, D.D., 2011. Transplantation
of neuronal-primed human bone marrow mesenchymal stem cells in
hemiparkinsonian rodents. PLoS ONE 6, e19025.
Kim, J.H., Auerbach, J.M., Rodriguez-Gomez, J.A., Velasco, I., Gavin, D., Lumelsky, N.,
Lee, S.H., Nguyen, J., Sanchez-Pernaute, R., Bankiewicz, K., McKay, R., 2002.
Dopamine neurons derived from embryonic stem cells function in an animal
model of Parkinson's disease. Nature 418, 50–56.
Kim, Y.J., Park, H.J., Lee, G., Bang, O.Y., Ahn, Y.H., Joe, E., Kim, H.O., Lee, P.H., 2009.
Neuroprotective effects of human mesenchymal stem cells on dopaminergic
neurons through anti-inﬂammatory action. Glia 57, 13–23.
Kishk, N., Abokrysha, N., 2011. Stem cell in neurological disorders. In:
Gholamrezanezhad, A. (Ed.), Stem Cells in Clinic and Research. In Tech, pp. 363–
400.
Kiss, L.E., Ferreira, H.S., Torrao, L., Bonifacio, M.J., Palma, P.N., Soares-da-Silva, P.,
Learmonth, D.A., 2010. Discovery of a long-acting, peripherally selective
inhibitor of catechol-O-methyltransferase. J. Med. Chem. 53, 3396–3411.
Kitagawa, M., Murata, J., Uesugi, H., Kikuchi, S., Saito, H., Tashiro, K., Sawamura, Y.,
2005. Two-year follow-up of chronic stimulation of the posterior subthalamic
white matter for tremor-dominant Parkinson's disease. Neurosurgery 56, 281–
289 (discussion 281–289).
Knudsen Gerber, D.S., 2011. Selegiline and rasagiline: twins or distant cousins?
Consult. Pharm. 26, 48–51.
Koller, W.C., 2003. Handbook of Parkinson's Disease. Marcel Dekker, New York.
Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B., Olanow, C.W., 2008. Lewy body-
like pathology in long-term embryonic nigral transplants in Parkinson's disease.
Nat. Med. 14, 504–506.
Kordower, J.H., Herzog, C.D., Dass, B., Bakay, R.A., Stansell III, J., Gasmi, M., Bartus, R.
T., 2006. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer
provides structural and functional neuroprotection and neurorestoration in
MPTP-treated monkeys. Ann. Neurol. 60, 706–715.
Kordower, J.H., Olanow, C.W., Dodiya, H.B., Chu, Y., Beach, T.G., Adler, C.H., Halliday,
G.M., Bartus, R.T., 2013. Disease duration and the integrity of the nigrostriatal
system in Parkinson's disease. Brain 136, 2419–2431.
Kordower, J.H., Rosenstein, J.M., Collier, T.J., Burke, M.A., Chen, E.Y., Li, J.M., Martel, L.,
Levey, A.E., Mufson, E.J., Freeman, T.B., Olanow, C.W., 1996. Functional fetal
nigral grafts in a patient with Parkinson's disease: chemoanatomic,
ultrastructural, and metabolic studies. J. Comp. Neurol. 370, 203–230.
Kotzbauer, P.T., Lampe, P.A., Heuckeroth, R.O., Golden, J.P., Creedon, D.J., Johnson Jr.,
E.M., Milbrandt, J., 1996. Neurturin, a relative of glial-cell-line-derived
neurotrophic factor. Nature 384, 467–470.
Lang, A.E., Gill, S., Patel, N.K., Lozano, A., Nutt, J.G., Penn, R., Brooks, D.J., Hotton, G.,
Moro, E., Heywood, P., Brodsky, M.A., Burchiel, K., Kelly, P., Dalvi, A., Scott, B.,
86 A.O. Pires et al. / Progress in Neurobiology 156 (2017) 69–89Stacy, M., Turner, D., Wooten, V.G., Elias, W.J., Laws, E.R., Dhawan, V., Stoessl, A.J.,
Matcham, J., Coffey, R.J., Traub, M., 2006. Randomized controlled trial of
intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson
disease. Ann. Neurol. 59, 459–466.
Lang, A.E., Lees, A., 2002. Management of Parkinson's disease: an evidence-based
review. Mov. Disord. 17 (Suppl. 4), S1–S166.
Larsen, J.P., Worm-Petersen, J., Siden, A., Gordin, A., Reinikainen, K., Leinonen, M.,
2003. The tolerability and efﬁcacy of entacapone over 3 years in patients with
Parkinson's disease. Eur. J. Neurol. 10, 137–146.
Lee, B., Lee, H., Nam, Y.R., Oh, J.H., Cho, Y.H., Chang, J.W., 2005. Enhanced expression
of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models.
Gene Ther. 12, 1215–1222.
Levy, Y.S., Bahat-Stroomza, M., Barzilay, R., Burshtein, A., Bulvik, S., Barhum, Y.,
Panet, H., Melamed, E., Offen, D., 2008. Regenerative effect of neural-induced
human mesenchymal stromal cells in rat models of Parkinson's disease.
Cytotherapy 10, 340–352.
LeWitt, P.A., Rezai, A.R., Leehey, M.A., Ojemann, S.G., Flaherty, A.W., Eskandar, E.N.,
Kostyk, S.K., Thomas, K., Sarkar, A., Siddiqui, M.S., Tatter, S.B., Schwalb, J.M.,
Poston, K.L., Henderson, J.M., Kurlan, R.M., Richard, I.H., Van Meter, L., Sapan, C.
V., During, M.J., Kaplitt, M.G., Feigin, A., 2011. AAV2-GAD gene therapy for
advanced Parkinson's disease: a double-blind, sham-surgery controlled,
randomised trial. Lancet Neurol. 10, 309–319.
Li, J.Y., Englund, E., Holton, J.L., Soulet, D., Hagell, P., Lees, A.J., Lashley, T., Quinn, N.P.,
Rehncrona, S., Bjorklund, A., Widner, H., Revesz, T., Lindvall, O., Brundin, P., 2008.
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest
host-to-graft disease propagation. Nat. Med. 14, 501–503.
Li, Y., Chen, J., Chen, X.G., Wang, L., Gautam, S.C., Xu, Y.X., Katakowski, M., Zhang, L.J.,
Lu, M., Janakiraman, N., Chopp, M., 2002. Human marrow stromal cell therapy
for stroke in rat: neurotrophins and functional recovery. Neurology 59, 514–523.
Lian, Q., Zhang, Y., Zhang, J., Zhang, H.K., Wu, X., Zhang, Y., Lam, F.F., Kang, S., Xia, J.C.,
Lai, W.H., Au, K.W., Chow, Y.Y., Siu, C.W., Lee, C.N., Tse, H.F., 2010. Functional
mesenchymal stem cells derived from human induced pluripotent stem cells
attenuate limb ischemia in mice. Circulation 121, 1113–1123.
Lin, Y.C., Ko, T.L., Shih, Y.H., Lin, M.Y., Fu, T.W., Hsiao, H.S., Hsu, J.Y., Fu, Y.S., 2011.
Human umbilical mesenchymal stem cells promote recovery after ischemic
stroke. Stroke 42, 2045–2053.
Lindvall, O., Brundin, P., Widner, H., Rehncrona, S., Gustavii, B., Frackowiak, R.,
Leenders, K.L., Sawle, G., Rothwell, J.C., Marsden, C.D., et al., 1990. Grafts of fetal
dopamine neurons survive and improve motor function in Parkinson's disease.
Science 247, 574–577.
Liu, J., Song, L., Jiang, C., Liu, Y., George, J., Ye, H., Cui, Z., 2012. Electrophysiological
properties and synaptic function of mesenchymal stem cells during neurogenic
differentiation – a mini-review. Int. J. Artif. Organs 35, 323–337.
Lopatina, T., Kalinina, N., Karagyaur, M., Stambolsky, D., Rubina, K., Revischin, A.,
Pavlova, G., Parfyonova, Y., Tkachuk, V., 2011. Adipose-derived stem cells
stimulate regeneration of peripheral nerves: BDNF secreted by these cells
promotes nerve healing and axon growth de novo. PLoS ONE 6, e17899.
Luo, J., Kaplitt, M.G., Fitzsimons, H.L., Zuzga, D.S., Liu, Y., Oshinsky, M.L., During, M.J.,
2002. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science
298, 425–429.
Maranis, S., Stamatis, D., Tsironis, C., Konitsiotis, S., 2012. Investigation of the
antidyskinetic site of action of metabotropic and ionotropic glutamate receptor
antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with
levodopa-induced dyskinesia. Eur. J. Pharmacol. 683, 71–77.
Marconi, S., Zwingers, T., 2014. Comparative efﬁcacy of selegiline versus rasagiline
in the treatment of early Parkinson's disease. Eur. Rev. Med. Pharmacol. Sci. 18,
1879–1882.
Marino, M.J., Conn, P.J., 2006. Glutamate-based therapeutic approaches: allosteric
modulators of metabotropic glutamate receptors. Curr. Opin. Pharmacol. 6, 98–
102.
Marks Jr., W.J., Bartus, R.T., Siffert, J., Davis, C.S., Lozano, A., Boulis, N., Vitek, J., Stacy,
M., Turner, D., Verhagen, L., Bakay, R., Watts, R., Guthrie, B., Jankovic, J., Simpson,
R., Tagliati, M., Alterman, R., Stern, M., Baltuch, G., Starr, P.A., Larson, P.S., Ostrem,
J.L., Nutt, J., Kieburtz, K., Kordower, J.H., Olanow, C.W., 2010. Gene delivery of
AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled
trial. Lancet Neurol. 9, 1164–1172.
Marks Jr., W.J., Ostrem, J.L., Verhagen, L., Starr, P.A., Larson, P.S., Bakay, R.A., Taylor, R.,
Cahn-Weiner, D.A., Stoessl, A.J., Olanow, C.W., Bartus, R.T., 2008. Safety and
tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus
serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-
label, phase I trial. Lancet Neurol. 7, 400–408.
Martinez Banaclocha, M., 2000. N-acetylcysteine elicited increase in complex I
activity in synaptic mitochondria from aged mice: implications for treatment of
Parkinson's disease. Brain Res. 859, 173–175.
Martinez-Banaclocha, M.A., 2012. N-acetyl-cysteine in the treatment of Parkinson's
disease. What are we waiting for? Med. Hypotheses 79, 8–12.
Maruyama, W., Takahashi, T., Youdim, M., Naoi, M., 2002. The anti-Parkinson drug,
rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human
dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109, 467–481.
Massano, J., Bhatia, K.P., 2012. Clinical approach to Parkinson's disease: features,
diagnosis, and principles of management. Cold Spring Harb. Perspect. Med. 2,
a008870.
Mathieu, P., Roca, V., Gamba, C., Del Pozo, A., Pitossi, F., 2012. Neuroprotective effects
of human umbilical cord mesenchymal stromal cells in an immunocompetent
animal model of Parkinson's disease. J. Neuroimmunol. 246, 43–50.McCoy, M.K., Martinez, T.N., Ruhn, K.A., Wrage, P.C., Keefer, E.W., Botterman, B.R.,
Tansey, K.E., Tansey, M.G., 2008. Autologous transplants of Adipose-Derived
Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of
Parkinson's disease. Exp. Neurol. 210, 14–29.
Meirelles Lda, S., Fontes, A.M., Covas, D.T., Caplan, A.I., 2009. Mechanisms involved
in the therapeutic properties of mesenchymal stem cells. Cytokine Growth
Factor Rev. 20, 419–427.
Meyer, A.K., Maisel, M., Hermann, A., Stirl, K., Storch, A., 2010. Restorative
approaches in Parkinson's disease: which cell type wins the race? J. Neurol. Sci.
289, 93–103.
Meyers, R., 1942. The modiﬁcation of alternating tremors, rigidity and festination by
surgery of the basal ganglia. Res. Publ. Nerv. Ment. Dis. Proc. 21, 602–665.
Meyers, R., 1951. Surgical experiments in the therapy of certain ‘extrapyramidal’
diseases: a current evaluation. Acta Psychiatr. Neurol. Suppl. 67, 1–42.
Mitchell, K.E., Weiss, M.L., Mitchell, B.M., Martin, P., Davis, D., Morales, L., Helwig, B.,
Beerenstrauch, M., Abou-Easa, K., Hildreth, T., Troyer, D., Medicetty, S., 2003.
Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 21, 50–60.
Monti, D.A., Zabrecky, G., Kremens, D., Liang, T.W., Wintering, N.A., Cai, J., Wei, X.,
Bazzan, A.J., Zhong, L., Bowen, B., Intenzo, C.M., Iacovitti, L., Newberg, A.B., 2016.
N-acetyl cysteine may support dopamine neurons in Parkinson's disease:
preliminary clinical and cell line data. PLoS ONE 11, e0157602.
Moro, E., Lozano, A.M., Pollak, P., Agid, Y., Rehncrona, S., Volkmann, J., Kulisevsky, J.,
Obeso, J.A., Albanese, A., Hariz, M.I., Quinn, N.P., Speelman, J.D., Benabid, A.L.,
Fraix, V., Mendes, A., Welter, M.L., Houeto, J.L., Cornu, P., Dormont, D., Tornqvist,
A.L., Ekberg, R., Schnitzler, A., Timmermann, L., Wojtecki, L., Gironell, A.,
Rodriguez-Oroz, M.C., Guridi, J., Bentivoglio, A.R., Contarino, M.F., Romito, L.,
Scerrati, M., Janssens, M., Lang, A.E., 2010. Long-term results of a multicenter
study on subthalamic and pallidal stimulation in Parkinson's disease. Mov.
Disord. 25, 578–586.
Muller, T., 2016. Emerging approaches in Parkinson's disease – adjunctive role of
saﬁnamide. Ther. Clin. Risk Manag. 12, 1151–1160.
Muller, T., Buttner, T., Gholipour, A.F., Kuhn, W., 2003. Coenzyme Q10
supplementation provides mild symptomatic beneﬁt in patients with
Parkinson's disease. Neurosci. Lett. 341, 201–204.
Munoz-Elias, G., Marcus, A.J., Coyne, T.M., Woodbury, D., Black, I.B., 2004. Adult bone
marrow stromal cells in the embryonic brain: engraftment, migration,
differentiation, and long-term survival. J. Neurosci. 24, 4585–4595.
Nandhagopal, R., McKeown, M.J., Stoessl, A.J., 2008. Functional imaging in Parkinson
disease. Neurology 70, 1478–1488.
Navntoft, C.A., Dreyer, J.K., 2016. How compensation breaks down in Parkinson's
disease: insights from modeling of denervated striatum. Mov. Disord. 31, 280–
289.
Neuhuber, B., Timothy Himes, B., Shumsky, J.S., Gallo, G., Fischer, I., 2005. Axon
growth and recovery of function supported by human bone marrow stromal
cells in the injured spinal cord exhibit donor variations. Brain Res. 1035, 73–85.
Nicoletti, F., Bockaert, J., Collingridge, G.L., Conn, P.J., Ferraguti, F., Schoepp, D.D.,
Wroblewski, J.T., Pin, J.P., 2011. Metabotropic glutamate receptors: from the
workbench to the bedside. Neuropharmacology 60, 1017–1041.
Niswender, C.M., Johnson, K.A., Weaver, C.D., Jones, C.K., Xiang, Z., Luo, Q., Rodriguez,
A.L., Marlo, J.E., de Paulis, T., Thompson, A.D., Days, E.L., Nalywajko, T., Austin, C.
A., Williams, M.B., Ayala, J.E., Williams, R., Lindsley, C.W., Conn, P.J., 2008.
Discovery, characterization, and antiparkinsonian effect of novel positive
allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol.
74, 1345–1358.
Nutt, J.G., Burchiel, K.J., Comella, C.L., Jankovic, J., Lang, A.E., Laws Jr., E.R., Lozano, A.
M., Penn, R.D., Simpson Jr., R.K., Stacy, M., Wooten, G.F., 2003. Randomized,
double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.
Neurology 60, 69–73.
Nutt, J.G., Woodward, W.R., Beckner, R.M., Stone, C.K., Berggren, K., Carter, J.H.,
Gancher, S.T., Hammerstad, J.P., Gordin, A.,1994. Effect of peripheral catechol-O-
methyltransferase inhibition on the pharmacokinetics and pharmacodynamics
of levodopa in parkinsonian patients. Neurology 44, 913–919.
Obeso, J.A., Olanow, C.W., Nutt, J.G., 2000. Levodopa motor complications in
Parkinson's disease. Trends Neurosci. 23, S2–S7.
Offen, D., Barhum, Y., Levy, Y.S., Burshtein, A., Panet, H., Cherlow, T., Melamed, E.,
2007. Intrastriatal transplantation of mouse bone marrow-derived stem cells
improves motor behavior in a mouse model of Parkinson's disease. J. Neural
Transm. Suppl. 72, 133–143.
Okun, M.S., 2013. Erratum: A closer look at unilateral versus bilateral deep brain
stimulation: results of the National Institutes of Health COMPARE cohort:
Clinical article. J. Neurosurg. 113, 1086.
Okun, M.S., Fernandez, H.H., Wu, S.S., Kirsch-Darrow, L., Bowers, D., Bova, F., Suelter,
M., Jacobson, C.E.t., Wang, X., Gordon Jr., C.W., Zeilman, P., Romrell, J., Martin, P.,
Ward, H., Rodriguez, R.L., Foote, K.D., 2009. Cognition and mood in Parkinson's
disease in subthalamic nucleus versus globus pallidus interna deep brain
stimulation: the COMPARE trial. Ann. Neurol. 65, 586–595.
Olanow, C.W., Brundin, P., 2013. Parkinson's disease and alpha synuclein: is
Parkinson's disease a prion-like disorder? Mov. Disord. 28, 31–40.
Olanow, C.W., Goetz, C.G., Kordower, J.H., Stoessl, A.J., Sossi, V., Brin, M.F., Shannon,
K.M., Nauert, G.M., Perl, D.P., Godbold, J., Freeman, T.B., 2003. A double-blind
controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.
Ann. Neurol. 54, 403–414.
Olanow, C.W., Hauser, R.A., Jankovic, J., Langston, W., Lang, A., Poewe, W., Tolosa, E.,
Stocchi, F., Melamed, E., Eyal, E., Rascol, O., 2008a. A randomized, double-blind,
placebo-controlled, delayed start study to assess rasagiline as a disease
A.O. Pires et al. / Progress in Neurobiology 156 (2017) 69–89 87modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design,
and baseline characteristics. Mov. Disord. 23, 2194–2201.
Olanow, C.W., Kieburtz, K., Schapira, A.H., 2008b. Why have we failed to achieve
neuroprotection in Parkinson's disease? Ann. Neurol. 64 (Suppl. 2), S101–S110.
Olanow, C.W., Rascol, O., Hauser, R., Feigin, P.D., Jankovic, J., Lang, A., Langston, W.,
Melamed, E., Poewe, W., Stocchi, F., Tolosa, E., 2009a. A double-blind, delayed-
start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268–1278.
Olanow, C.W., Stern, M.B., Sethi, K., 2009b. The scientiﬁc and clinical basis for the
treatment of Parkinson disease (2009). Neurology 72, S1–S136.
Olanow, C.W., Watts, R.L., Koller, W.C., 2001. An algorithm (decision tree) for the
management of Parkinson's disease (2001): treatment guidelines. Neurology
56, S1–S88.
Onofrj, M., Bonanni, L., Thomas, A., 2008. An expert opinion on saﬁnamide in
Parkinson's disease. Expert Opin. Investig. Drugs 17, 1115–1125.
Paek, S.B., Min, H.K., Kim, I., Knight, E.J., Baek, J.J., Bieber, A.J., Lee, K.H., Chang, S.Y.,
2015. Frequency-dependent functional neuromodulatory effects on the motor
network by ventral lateral thalamic deep brain stimulation in swine.
Neuroimage 105, 181–188.
Pandey, S., 2012. Parkinson's disease: recent advances. J. Assoc. Physicians India 60,
30–32.
Parish, C.L., Castelo-Branco, G., Rawal, N., Tonnesen, J., Sorensen, A.T., Salto, C.,
Kokaia, M., Lindvall, O., Arenas, E., 2008. Wnt5a-treated midbrain neural stem
cells improve dopamine cell replacement therapy in parkinsonian mice. J. Clin.
Invest. 118, 149–160.
Park, H.J., Shin, J.Y., Lee, B.R., Kim, H.O., Lee, P.H., 2012. Mesenchymal stem cells
augment neurogenesis in the subventricular zone and enhance differentiation
of neural precursor cells into dopaminergic neurons in the substantia nigra of a
parkinsonian model. Cell Transplant. 21, 1629–1640.
Park, S., Lee, K.S., Lee, Y.J., Shin, H.A., Cho, H.Y., Wang, K.C., Kim, Y.S., Lee, H.T., Chung,
K.S., Kim, E.Y., Lim, J., 2004. Generation of dopaminergic neurons in vitro from
human embryonic stem cells treated with neurotrophic factors. Neurosci. Lett.
359, 99–103.
Parkinson, J., 1817. An Essay on the Shaking Palsy. Whittingham & Rowland, London.
Parkinson Study, G., 2004. The safety and tolerability of a mixed lineage kinase
inhibitor (CEP-1347) in PD. Neurology 62, 330–332.
Parkinson Study Group, P.I., 2007. Mixed lineage kinase inhibitor CEP-1347 fails to
delay disability in early Parkinson disease. Neurology 69, 1480–1490.
Parkinson Study Group, Q.E.I., Beal, M.F., Oakes, D., Shoulson, I., Henchcliffe, C.,
Galpern, W.R., Haas, R., Juncos, J.L., Nutt, J.G., Voss, T.S., Ravina, B., Shults, C.M.,
Helles, K., Snively, V., Lew, M.F., Griebner, B., Watts, A., Gao, S., Pourcher, E., Bond,
L., Kompoliti, K., Agarwal, P., Sia, C., Jog, M., Cole, L., Sultana, M., Kurlan, R.,
Richard, I., Deeley, C., Waters, C.H., Figueroa, A., Arkun, A., Brodsky, M., Ondo, W.
G., Hunter, C.B., Jimenez-Shahed, J., Palao, A., Miyasaki, J.M., So, J., Tetrud, J., Reys,
L., Smith, K., Singer, C., Blenke, A., Russell, D.S., Cotto, C., Friedman, J.H., Lannon,
M., Zhang, L., Drasby, E., Kumar, R., Subramanian, T., Ford, D.S., Grimes, D.A.,
Cote, D., Conway, J., Siderowf, A.D., Evatt, M.L., Sommerfeld, B., Lieberman, A.N.,
Okun, M.S., Rodriguez, R.L., Merritt, S., Swartz, C.L., Martin, W.R., King, P., Stover,
N., Guthrie, S., Watts, R.L., Ahmed, A., Fernandez, H.H., Winters, A., Mari, Z.,
Dawson, T.M., Dunlop, B., Feigin, A.S., Shannon, B., Nirenberg, M.J., Ogg, M.,
Ellias, S.A., Thomas, C.A., Frei, K., Bodis-Wollner, I., Glazman, S., Mayer, T., Hauser,
R.A., Pahwa, R., Langhammer, A., Ranawaya, R., Derwent, L., Sethi, K.D., Farrow,
B., Prakash, R., Litvan, I., Robinson, A., Sahay, A., Gartner, M., Hinson, V.K.,
Markind, S., Pelikan, M., Perlmutter, J.S., Hartlein, J., Molho, E., Evans, S., Adler, C.
H., Duffy, A., Lind, M., Elmer, L., Davis, K., Spears, J., Wilson, S., Leehey, M.A.,
Hermanowicz, N., Niswonger, S., Shill, H.A., Obradov, S., Rajput, A., Cowper, M.,
Lessig, S., Song, D., Fontaine, D., Zadikoff, C., Williams, K., Blindauer, K.A.,
Bergholte, J., Propsom, C.S., Stacy, M.A., Field, J., Mihaila, D., Chilton, M., Uc, E.Y.,
Sieren, J., Simon, D.K., Kraics, L., Silver, A., Boyd, J.T., Hamill, R.W., Ingvoldstad, C.,
Young, J., Thomas, K., Kostyk, S.K., Wojcieszek, J., Pfeiffer, R.F., Panisset, M.,
Beland, M., Reich, S.G., Cines, M., Zappala, N., Rivest, J., Zweig, R., Lumina, L.P.,
Hilliard, C.L., Grill, S., Kellermann, M., Tuite, P., Rolandelli, S., Kang, U.J., Young, J.,
Rao, J., Cook, M.M., Severt, L., Boyar, K., 2014. A randomized clinical trial of high-
dosage coenzyme Q10 in early Parkinson disease: no evidence of beneﬁt. JAMA
Neurol. 71, 543–552.
Parkinson Study Group, 1989. DATATOP: a multicenter controlled clinical trial in
early Parkinson's disease. Arch. Neurol. 46, 1052–1060.
Parkinson Study Group,1997. Entacapone improves motor ﬂuctuations in levodopa-
treated Parkinson's disease patients. Ann. Neurol. 42, 747–755.
Parkinson Study Group, 2000. Pramipexole vs. levodopa as initial treatment for
Parkinson disease: a randomized controlled trial. JAMA 284, 1931–1938.
Parkinson Study Group, 2002. A controlled trial of rasagiline in early Parkinson
disease: the TEMPO Study. Arch. Neurol. 59, 1937–1943.
Pereira, E.A., Aziz, T.Z., 2006. Surgical insights into Parkinson's disease. J. R. Soc. Med.
99, 238–244.
Peretz, C., Segev, H., Rozani, V., Gurevich, T., El-Ad, B., Tsamir, J., Giladi, N., 2016.
Comparison of selegiline and rasagiline therapies in Parkinson disease: a real-
life study. Clin. Neuropharmacol. 39, 227–231.
Perez-Lloret, S., Rascol, O., 2016. The safety and efﬁcacy of saﬁnamide mesylate for
the treatment of Parkinson's disease. Expert Rev. Neurother. 16, 245–258.
Perlow, M.J., Freed, W.J., Hoffer, B.J., Seiger, A., Olson, L., Wyatt, R.J., 1979. Brain grafts
reduce motor abnormalities produced by destruction of nigrostriatal dopamine
system. Science 204, 643–647.
Perrier, A.L., Tabar, V., Barberi, T., Rubio, M.E., Bruses, J., Topf, N., Harrison, N.L.,
Studer, L., 2004. Derivation of midbrain dopamine neurons from human
embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 101, 12543–12548.Perrone-Capano, C., Di Porzio, U., 2000. Genetic and epigenetic control of midbrain
dopaminergic neuron development. Int. J. Dev. Biol. 44, 679–687.
Pfeiffer, R.F., Gutmann, L., Hull Jr., K.L., Bottini, P.B., Sherry, J.H., 2007. Continued
efﬁcacy and safety of subcutaneous apomorphine in patients with advanced
Parkinson's disease. Parkinsonism Relat. Disord. 13, 93–100.
Pﬁsterer, U., Kirkeby, A., Torper, O., Wood, J., Nelander, J., Dufour, A., Bjorklund, A.,
Lindvall, O., Jakobsson, J., Parmar, M., 2011. Direct conversion of human
ﬁbroblasts to dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 108, 10343–
10348.
Phinney, D.G., Prockop, D.J., 2007. Concise review: mesenchymal stem/multipotent
stromal cells: the state of transdifferentiation and modes of tissue repair –
current views. Stem Cells 25, 2896–2902.
Plaha, P., Ben-Shlomo, Y., Patel, N.K., Gill, S.S., 2006. Stimulation of the caudal zona
incerta is superior to stimulation of the subthalamic nucleus in improving
contralateral parkinsonism. Brain 129, 1732–1747.
Plaha, P., Gill, S.S., 2005. Bilateral deep brain stimulation of the pedunculopontine
nucleus for Parkinson's disease. Neuroreport 16, 1883–1887.
Poewe, W.H., Deuschl, G., Gordin, A., Kultalahti, E.R., Leinonen, M., 2002. Efﬁcacy and
safety of entacapone in Parkinson's disease patients with suboptimal levodopa
response: a 6-month randomized placebo-controlled double-blind study in
Germany and Austria (Celomen study). Acta Neurol. Scand. 105, 245–255.
Politis, M., Lindvall, O., 2012a. Clinical application of stem cell therapy in Parkinson's
disease. BMC Med. 10, 1.
Politis, M., Lindvall, O., 2012b. Clinical application of stem cell therapy in Parkinson's
disease. BMC Med. 10, 1–7.
Pope-Coleman, A., Tinker, J.P., Schneider, J.S., 2000. Effects of GM1 ganglioside
treatment on pre- and postsynaptic dopaminergic markers in the striatum of
parkinsonian monkeys. Synapse 36, 120–128.
Rascol, O., 2009. Disease-modiﬁcation” trials in Parkinson disease: target
populations, endpoints and study design. Neurology 72, S51–S58.
Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E., Lang, A.E., 2000. A
ﬁve-year study of the incidence of dyskinesia in patients with early Parkinson's
disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl.
J. Med. 342, 1484–1491.
Rascol, O., Lozano, A., Stern, M., Poewe, W., 2011. Milestones in Parkinson's disease
therapeutics. Mov. Disord. 26, 1072–1082.
Rinne, U.K., Larsen, J.P., Siden, A., Worm-Petersen, J., 1998. Entacapone enhances the
response to levodopa in parkinsonian patients with motor ﬂuctuations.
Nomecomt Study Group. Neurology 51, 1309–1314.
Rocha, J.F., Falcao, A., Santos, A., Pinto, R., Lopes, N., Nunes, T., Wright, L.C., Vaz-da-
Silva, M., Soares-da-Silva, P., 2014. Effect of opicapone and entacapone upon
levodopa pharmacokinetics during three daily levodopa administrations. Eur. J.
Clin. Pharmacol. 70, 1059–1071.
Rodnitzky, R.L., 2012. Upcoming treatments in Parkinson's disease, including gene
therapy. Parkinsonism Relat. Disord. 18 (Suppl. 1), S37–S40.
Rowland, N.C., Starr, P.A., Larson, P.S., Ostrem, J.L., Marks Jr., W.J., Lim, D.A., 2015.
Combining cell transplants or gene therapy with deep brain stimulation for
Parkinson's disease. Mov. Disord. 30, 190–195.
Roy, N.S., Cleren, C., Singh, S.K., Yang, L., Beal, M.F., Goldman, S.A., 2006. Functional
engraftment of human ES cell-derived dopaminergic neurons enriched by
coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12,
1259–1268.
Sackeim, H.A., George, M.S., 2008. Brain stimulation-basic, translational, and clinical
research in neuromodulation: why a new journal? Brain Stimul. 1, 4–6.
Sadan, O., Bahat-Stromza, M., Barhum, Y., Levy, Y.S., Pisnevsky, A., Peretz, H., Ilan, A.
B., Bulvik, S., Shemesh, N., Krepel, D., Cohen, Y., Melamed, E., Offen, D., 2009.
Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model
of Parkinson disease. Stem Cells Dev. 18, 1179–1190.
Salama, M., Eldakroory, S.A., Eltantawy, D., Ghanem, A.A., Elghaffar, H.A., Elhusseiny,
M., Elhak, S.G., 2012. Regenerative effects of umbilical cord matrix cells (UCMCs)
in a rodent model of rotenone neurotoxicity. Environ. Toxicol. Pharmacol. 34,
338–344.
Salgado, A.J., Oliveira, J.T., Pedro, A.J., Reis, R.L., 2006. Adult stem cells in bone and
cartilage tissue engineering. Curr. Stem Cell Res. Ther. 1, 345–364.
Sanchez-Danes, A., Richaud-Patin, Y., Carballo-Carbajal, I., Jimenez-Delgado, S., Caig,
C., Mora, S., Di Guglielmo, C., Ezquerra, M., Patel, B., Giralt, A., Canals, J.M., Memo,
M., Alberch, J., Lopez-Barneo, J., Vila, M., Cuervo, A.M., Tolosa, E., Consiglio, A.,
Raya, A., 2012. Disease-speciﬁc phenotypes in dopamine neurons from human
iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med.
4, 380–395.
Sanchez-Pernaute, R., Studer, L., Bankiewicz, K.S., Major, E.O., McKay, R.D., 2001. In
vitro generation and transplantation of precursor-derived human dopamine
neurons. J. Neurosci. Res. 65, 284–288.
Sawamoto, K., Nakao, N., Kakishita, K., Ogawa, Y., Toyama, Y., Yamamoto, A.,
Yamaguchi, M., Mori, K., Goldman, S.A., Itakura, T., Okano, H., 2001. Generation
of dopaminergic neurons in the adult brain from mesencephalic precursor cells
labeled with a nestin-GFP transgene. J. Neurosci. 21, 3895–3903.
Schapira, A.H., 2005. Present and future drug treatment for Parkinson's disease. J.
Neurol. Neurosurg. Psychiatry 76, 1472–1478.
Schneider, J.S., Cambi, F., Gollomp, S.M., Kuwabara, H., Brasic, J.R., Leiby, B., Sendek,
S., Wong, D.F., 2015. GM1 ganglioside in Parkinson's disease: pilot study of
effects on dopamine transporter binding. J. Neurol. Sci. 356, 118–123.
Schneider, J.S., Gollomp, S.M., Sendek, S., Colcher, A., Cambi, F., Du, W., 2013. A
randomized, controlled, delayed start trial of GM1 ganglioside in treated
Parkinson's disease patients. J. Neurol. Sci. 324, 140–148.
88 A.O. Pires et al. / Progress in Neurobiology 156 (2017) 69–89Schneider, J.S., Kean, A., DiStefano, L., 1995. GM1 ganglioside rescues substantia
nigra pars compacta neurons and increases dopamine synthesis in residual
nigrostriatal dopaminergic neurons in MPTP-treated mice. J. Neurosci. Res. 42,
117–123.
Schneider, J.S., Roeltgen, D.P., Mancall, E.L., Chapas-Crilly, J., Rothblat, D.S., Tatarian,
G.T., 1998. Parkinson's disease: improved function with GM1 ganglioside
treatment in a randomized placebo-controlled study. Neurology 50, 1630–1636.
Schneider, J.S., Sendek, S., Daskalakis, C., Cambi, F., 2010. GM1 ganglioside in
Parkinson's disease: results of a ﬁve year open study. J. Neurol. Sci. 292, 45–51.
Schupbach, W.M., Chastan, N., Welter, M.L., Houeto, J.L., Mesnage, V., Bonnet, A.M.,
Czernecki, V., Maltete, D., Hartmann, A., Mallet, L., Pidoux, B., Dormont, D.,
Navarro, S., Cornu, P., Mallet, A., Agid, Y., 2005. Stimulation of the subthalamic
nucleus in Parkinson's disease: a 5 year follow up. J. Neurol. Neurosurg.
Psychiatry 76, 1640–1644.
Schwalb, J.M., Hamani, C., 2008. The history and future of deep brain stimulation.
Neurotherapeutics 5, 3–13.
Schwarz, S.C., Wittlinger, J., Schober, R., Storch, A., Schwarz, J., 2006. Transplantation
of human neural precursor cells in the 6-OHDA lesioned rats: effect of
immunosuppression with cyclosporine A. Parkinsonism Relat. Disord. 12, 302–
308.
Scott, L.J., 2016. Opicapone: a review in Parkinson's disease. Drugs 76, 1293–1300.
Seet, R.C., Lim, E.C., Tan, J.J., Quek, A.M., Chow, A.W., Chong, W.L., Ng, M.P., Ong, C.N.,
Halliwell, B., 2014. Does high-dose coenzyme Q10 improve oxidative damage
and clinical outcomes in Parkinson's disease? Antioxid. Redox Signal. 21, 211–
217.
Seo, J.H., Cho, S.R., 2012. Neurorestoration induced by mesenchymal stem cells:
potential therapeutic mechanisms for clinical trials. Yonsei Med. J. 53, 1059–
1067.
Shamekh, R., Saporta, S., Cameron, D.F., Willing, A.E., Sanberg, C.D., Johe, K., Sanberg,
P.R., 2008. Effects of Sertoli cell-conditioned medium on ventral midbrain
neural stem cells: a preliminary report. Neurotox. Res. 13, 241–246.
Sherer, T.B., Fiske, B.K., Svendsen, C.N., Lang, A.E., Langston, J.W., 2006. Crossroads in
GDNF therapy for Parkinson's disease. Mov. Disord. 21, 136–141.
Shetty, P., Ravindran, G., Sarang, S., Thakur, A.M., Rao, H.S., Viswanathan, C., 2009.
Clinical grade mesenchymal stem cells transdifferentiated under xenofree
conditions alleviates motor deﬁciencies in a rat model of Parkinson's disease.
Cell Biol. Int. 33, 830–838.
Shetty, P., Thakur, A.M., Viswanathan, C., 2013. Dopaminergic cells, derived from a
high efﬁciency differentiation protocol from umbilical cord derived
mesenchymal stem cells, alleviate symptoms in a Parkinson's disease rodent
model. Cell Biol. Int. 37, 167–180.
Shintani, A., Nakao, N., Kakishita, K., Itakura, T., 2007. Protection of dopamine
neurons by bone marrow stromal cells. Brain Res. 1186, 48–55.
Shulman, L.M., Taback, R.L., Bean, J., Weiner, W.J., 2001. Comorbidity of the
nonmotor symptoms of Parkinson's disease. Mov. Disord. 16, 507–510.
Shulman, L.M., Taback, R.L., Rabinstein, A.A., Weiner, W.J., 2002. Non-recognition of
depression and other non-motor symptoms in Parkinson's disease.
Parkinsonism Relat. Disord. 8, 193–197.
Shults, C.W., Oakes, D., Kieburtz, K., Beal, M.F., Haas, R., Plumb, S., Juncos, J.L., Nutt, J.,
Shoulson, I., Carter, J., Kompoliti, K., Perlmutter, J.S., Reich, S., Stern, M., Watts, R.
L., Kurlan, R., Molho, E., Harrison, M., Lew, M., Parkinson Study, G., 2002. Effects
of coenzyme Q10 in early Parkinson disease: evidence of slowing of the
functional decline. Arch. Neurol. 59, 1541–1550.
Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., Paisan-
Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G., Kruger, R., Federoff, M., Klein,
C., Goate, A., Perlmutter, J., Bonin, M., Nalls, M.A., Illig, T., Gieger, C., Houlden, H.,
Steffens, M., Okun, M.S., Racette, B.A., Cookson, M.R., Foote, K.D., Fernandez, H.
H., Traynor, B.J., Schreiber, S., Arepalli, S., Zonozi, R., Gwinn, K., van der Brug, M.,
Lopez, G., Chanock, S.J., Schatzkin, A., Park, Y., Hollenbeck, A., Gao, J., Huang, X.,
Wood, N.W., Lorenz, D., Deuschl, G., Chen, H., Riess, O., Hardy, J.A., Singleton, A.
B., Gasser, T., 2009. Genome-wide association study reveals genetic risk
underlying Parkinson's disease. Nat. Genet. 41, 1308–1312.
Smith, Y., Wichmann, T., Factor, S.A., DeLong, M.R., 2012. Parkinson's disease
therapeutics: new developments and challenges since the introduction of
levodopa. Neuropsychopharmacology 37, 213–246.
Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G.W., Cook, E.G., Hargus, G., Blak,
A., Cooper, O., Mitalipova, M., Isacson, O., Jaenisch, R., 2009. Parkinson's disease
patient-derived induced pluripotent stem cells free of viral reprogramming
factors. Cell 136, 964–977.
Somoza, R., Juri, C., Baes, M., Wyneken, U., Rubio, F.J., 2010. Intranigral
transplantation of epigenetically induced BDNF-secreting human mesenchymal
stem cells: implications for cell-based therapies in Parkinson's disease. Biol.
Blood Marrow Transplant. 16, 1530–1540.
Soulas, T., Gurruchaga, J.M., Palﬁ, S., Cesaro, P., Nguyen, J.P., Fenelon, G., 2008.
Attempted and completed suicides after subthalamic nucleus stimulation for
Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 79, 952–954.
Stocchi, F., Arnold, G., Onofrj, M., Kwiecinski, H., Szczudlik, A., Thomas, A.,
Bonuccelli, U., Van Dijk, A., Cattaneo, C., Sala, P., Fariello, R.G., Saﬁnamide
Parkinson's Study, G., 2004. Improvement of motor function in early Parkinson
disease by saﬁnamide. Neurology 63, 746–748.
Stocchi, F., Torti, M., 2016. Adjuvant therapies for Parkinson's disease: critical
evaluation of saﬁnamide. Drug Des. Devel. Ther. 10, 609–618.
Storch, A., Jost, W.H., Vieregge, P., Spiegel, J., Greulich, W., Durner, J., Muller, T.,
Kupsch, A., Henningsen, H., Oertel, W.H., Fuchs, G., Kuhn, W., Niklowitz, P., Koch,
R., Herting, B., Reichmann, H., German Coenzyme, Q.S.G., 2007. Randomized,double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q
(10) in Parkinson disease. Arch. Neurol. 64, 938–944.
Storch, A., Paul, G., Csete, M., Boehm, B.O., Carvey, P.M., Kupsch, A., Schwarz, J., 2001.
Long-term proliferation and dopaminergic differentiation of human
mesencephalic neural precursor cells. Exp. Neurol. 170, 317–325.
Storch, A., Sabolek, M., Milosevic, J., Schwarz, S.C., Schwarz, J., 2004. Midbrain-
derived neural stem cells: from basic science to therapeutic approaches. Cell
Tissue Res. 318, 15–22.
Stowe, R., Ives, N., Clarke, C.E., Handley, K., Furmston, A., Deane, K., van Hilten, J.J.,
Wheatley, K., Gray, R., 2011. Meta-analysis of the comparative efﬁcacy and safety
of adjuvant treatment to levodopa in later Parkinson's disease. Mov. Disord. 26,
587–598.
Strutt, A.M., Simpson, R., Jankovic, J., York, M.K., 2012. Changes in cognitive-
emotional and physiological symptoms of depression following STN-DBS for the
treatment of Parkinson's disease. Eur. J. Neurol. 19, 121–127.
Svendsen, C.N., Caldwell, M.A., Shen, J., ter Borg, M.G., Rosser, A.E., Tyers, P., Karmiol,
S., Dunnett, S.B., 1997. Long-term survival of human central nervous system
progenitor cells transplanted into a rat model of Parkinson's disease. Exp.
Neurol. 148, 135–146.
Svendsen, C.N., Clarke, D.J., Rosser, A.E., Dunnett, S.B., 1996. Survival and
differentiation of rat and human epidermal growth factor-responsive precursor
cells following grafting into the lesioned adult central nervous system. Exp.
Neurol. 137, 376–388.
Swistowski, A., Peng, J., Liu, Q., Mali, P., Rao, M.S., Cheng, L., Zeng, X., 2010. Efﬁcient
generation of functional dopaminergic neurons from human induced
pluripotent stem cells under deﬁned conditions. Stem Cells 28, 1893–1904.
Taba, H.A., Wu, S.S., Foote, K.D., Hass, C.J., Fernandez, H.H., Malaty, I.A., Rodriguez, R.
L., Dai, Y., Zeilman, P.R., Jacobson, C.E., Okun, M.S., 2010. A closer look at
unilateral versus bilateral deep brain stimulation: results of the National
Institutes of Health COMPARE cohort. J. Neurosurg. 113, 1224–1229.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka,
S., 2007. Induction of pluripotent stem cells from adult human ﬁbroblasts by
deﬁned factors. Cell 131, 861–872.
Takahashi, K., Yamanaka, S., 2006. Induction of pluripotent stem cells from mouse
embryonic and adult ﬁbroblast cultures by deﬁned factors. Cell 126, 663–676.
Tarazi, F.I., Sahli, Z.T., Wolny, M., Mousa, S.A., 2014. Emerging therapies for
Parkinson's disease: from bench to bedside. Pharmacol. Ther. 144, 123–133.
Teixeira, F.G., Carvalho, M.M., Panchalingam, K.M., Rodrigues, A.J., Mendes-Pinheiro,
B., Anjo, S., Manadas, B., Behie, L.A., Sousa, N., Salgado, A.J., 2016a. Impact of the
secretome of human mesenchymal stem cells on brain structure and animal
behavior in a rat model of Parkinson's disease. Stem Cells Transl. Med..
Teixeira, F.G., Carvalho, M.M., Sousa, N., Salgado, A.J., 2013. Mesenchymal stem cells
secretome: a new paradigm for central nervous system regeneration? Cell. Mol.
Life Sci. 70, 3871–3882.
Teixeira, F.G., Panchalingam, K.M., Assuncao-Silva, R., Serra, S.C., Mendes-Pinheiro,
B., Patricio, P., Jung, S., Anjo, S.I., Manadas, B., Pinto, L., Sousa, N., Behie, L.A.,
Salgado, A.J., 2016b. Modulation of the mesenchymal stem cell secretome using
computer-controlled bioreactors: impact on neuronal cell proliferation. Surv.
Differ. Sci. Rep. 6, 27791.
Thomas, M.G., Stone, L., Evill, L., Ong, S., Ziman, M., Hool, L., 2011. Bone marrow
stromal cells as replacement cells for Parkinson's disease: generation of an
anatomical but not functional neuronal phenotype. Transl. Res. 157, 56–63.
Trzaska, K.A., Kuzhikandathil, E.V., Rameshwar, P., 2007. Speciﬁcation of a
dopaminergic phenotype from adult human mesenchymal stem cells. Stem
Cells 25, 2797–2808.
Venkataramana, N.K., Kumar, S.K., Balaraju, S., Radhakrishnan, R.C., Bansal, A., Dixit,
A., Rao, D.K., Das, M., Jan, M., Gupta, P.K., Totey, S.M., 2010. Open-labeled study of
unilateral autologous bone-marrow-derived mesenchymal stem cell
transplantation in Parkinson's disease. Transl. Res. 155, 62–70.
Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Sudhof, T.C., Wernig, M., 2010.
Direct conversion of ﬁbroblasts to functional neurons by deﬁned factors. Nature
463, 1035–1041.
Wakabayashi, K., Nagai, A., Sheikh, A.M., Shiota, Y., Narantuya, D., Watanabe, T.,
Masuda, J., Kobayashi, S., Kim, S.U., Yamaguchi, S., 2010. Transplantation of
human mesenchymal stem cells promotes functional improvement and
increased expression of neurotrophic factors in a rat focal cerebral ischemia
model. J. Neurosci. Res. 88, 1017–1025.
Wang, F., Yasuhara, T., Shingo, T., Kameda, M., Tajiri, N., Yuan, W.J., Kondo, A., Kadota,
T., Baba, T., Tayra, J.T., Kikuchi, Y., Miyoshi, Y., Date, I., 2010. Intravenous
administration of mesenchymal stem cells exerts therapeutic effects on
parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-
derived factor-1alpha. BMC Neurosci. 11, 1–9.
Wang, Y., Yang, J., Li, H., Wang, X., Zhu, L., Fan, M., 2013. Hypoxia promotes
dopaminergic differentiation of mesenchymal stem cells and shows beneﬁts for
transplantation in a rat model of Parkinson's disease. PLoS ONE 8, e54296.
Wei, X., Du, Z., Zhao, L., Feng, D., Wei, G., He, Y., Tan, J., Lee, W.H., Hampel, H., Dodel,
R., Johnstone, B.H., March, K.L., Farlow, M.R., Du, Y., 2009. IFATS collection: the
conditioned media of adipose stromal cells protect against hypoxia-ischemia-
induced brain damage in neonatal rats. Stem Cells 27, 478–488.
Weiss, M.L., Medicetty, S., Bledsoe, A.R., Rachakatla, R.S., Choi, M., Merchav, S., Luo,
Y., Rao, M.S., Velagaleti, G., Troyer, D., 2006. Human umbilical cord matrix stem
cells: preliminary characterization and effect of transplantation in a rodent
model of Parkinson's disease. Stem Cells 24, 781–792.
Wenning, G.K., Odin, P., Morrish, P., Rehncrona, S., Widner, H., Brundin, P., Rothwell,
J.C., Brown, R., Gustavii, B., Hagell, P., Jahanshahi, M., Sawle, G., Bjorklund, A.,
Brooks, D.J., Marsden, C.D., Quinn, N.P., Lindvall, O., 1997. Short- and long-term
A.O. Pires et al. / Progress in Neurobiology 156 (2017) 69–89 89survival and function of unilateral intrastriatal dopaminergic grafts in
Parkinson's disease. Ann. Neurol. 42, 95–107.
Wernig, M., Zhao, J.P., Pruszak, J., Hedlund, E., Fu, D., Soldner, F., Broccoli, V.,
Constantine-Paton, M., Isacson, O., Jaenisch, R., 2008. Neurons derived from
reprogrammed ﬁbroblasts functionally integrate into the fetal brain and
improve symptoms of rats with Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A.
105, 5856–5861.
Wichmann, T., DeLong, M.R., 2016. Deep brain stimulation for movement disorders
of basal ganglia origin: restoring function or functionality? Neurotherapeutics
13, 264–283.
Widner, H., Tetrud, J., Rehncrona, S., Snow, B., Brundin, P., Gustavii, B., Bjorklund, A.,
Lindvall, O., Langston, J.W., 1992. Bilateral fetal mesencephalic grafting in two
patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). N. Engl. J. Med. 327, 1556–1563.
Wright, K.T., El Masri, W., Osman, A., Roberts, S., Chamberlain, G., Ashton, B.A.,
Johnson, W.E., 2007. Bone marrow stromal cells stimulate neurite outgrowth
over neural proteoglycans (CSPG), myelin associated lipoprotein and Novo-A.
Biochem. Biophys. Res. Common. 354, 559–566.
Xin, H., Li, Y., Buller, B., Katakowski, M., Zhang, Y., Wang, X., Shang, X., Zhang, Z.G.,
Chopp, M., 2012. Exosmic-mediated transfer of miR-133b from multipotent
mesenchymal stromal cells to neural cells contributes to neurite outgrowth.
Stem Cells 30, 1556–1564.
Yadav, A., Agarwal, S., Tiwari, S.K., Chaturvedi, R.K., 2014. Mitochondria: prospective
targets for neuroprotection in Parkinson's disease. Curr. Pharm. Des. 20,
5558–5573.Yang, C.C., Shih, Y.H., Ko, M.H., Hsu, S.Y., Cheng, H., Fu, Y.S., 2008a. Transplantation of
human umbilical mesenchymal stem cells from Wharton's jelly after complete
transaction of the rat spinal cord. PLoS ONE 3, e3336.
Yang, D., Zhang, Z.J., Oldenburg, M., Ayala, M., Zhang, S.C., 2008b. Human embryonic
stem cell-derived dopaminergic neurons reverse functional deﬁcit in
parkinsonian rats. Stem Cells 26, 55–63.
Yao, Y., Huang, C., Gu, P., Wen, T., 2016. Combined MSC-secreted factors and neural
stem cell transplantation promote functional recovery of PD rats. Cell
Transplant. 25, 1101–1113.
Yi, B.R., Kim, S.U., Choi, K.C., 2013. Development and application of neural stem cells
for treating various human neurological diseases in animal models. Lab. Anima.
Res. 29, 131–137.
Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., Melton, D.A., 2008. In vivo
reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455,
627–632.
Zhou, Y., Sun, M., Li, H., Yan, M., He, Z., Wang, W., Lu, S., 2013a. Recovery of behavioral
symptoms in hemi-parkinsonian rhesus monkeys through combined gene and
stem cell therapy. Cytotherapy 15, 467–480.
Zhou, Y., Xu, H., Xu, W., Wang, B., Wu, H., Tao, Y., Zhang, B., Wang, M., Mao, F., Yan, Y.,
Gao, S., Gu, H., Zhu, W., Qian, H., 2013b. Exosomes released by human umbilical
cord mesenchymal stem cells protect against capsulation-induced renal
oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res. Ther. 4, 1–13.
Zhu, Y.G., Feng, X.M., Abbott, J., Fang, X.H., Hao, Q., Monsel, A., Qu, J.M., Matthay, M.
A., Lee, J.W., 2013. Human mesenchymal stem cell microvesicles for treatment
of E. coil end toxin-induced acute lung injury in mice. Stem Cells 32, 116–125.
